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Abstract 
At the 3M facility in Cottage Grove, Minnesota, Ammonium Perfluorooctanoate 
(APFO) was formulated as a polymerization aid used in the production of 
commercial and consumer products from 1947-2002.  APFO is in a class of 
perfluorocarbons (PFCs)—inert chemicals—that for many years were thought to 
be nontoxic.  More recently, however, a growing interest has surfaced and 
attention has turned to the health effects from exposure to APFO, and its 
dissociated anion perfluorooctanoic acid (PFOA).  Researchers and public health 
officials have noted the persistence of APFO and PFOA in the environment along 
with data that show it remains for a long period in the human body (Houde at al., 
2006; and Olsen et al., 2007).  Adverse health outcomes reported from several 
animal studies in conjunction with the noted positive association between APFO 
exposure and an increased risk of dying from prostate cancer found in workers at 
the 3M Cottage Grove, Minnesota location, have been the impetus for this 
research (Lundin et al., 2009; Butenhoff et al., 2002; and Kennedy et al., 2004).  
The current study evaluated the risk of death in workers based on a newly 
developed APFO/PFOA quantitative exposure data matrix.  We evaluated 
workers’ health outcomes using annual exposure estimates.  These estimates were 
based on two exposure models; a cumulative model (potential cumulative dose, 
PCD) and a cumulative clearance weighted model (CCWD).  Compared to 
previous epidemiological studies with this cohort, this study estimated a 
quantitative level of exposure that potentially contributes to negative health 
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effects in humans.  This was a retrospective occupational mortality study of 9,027 
3M employees who worked a minimum of one year at one of two 3M locations 
(Cottage Grove and St. Paul plants) in Minnesota.  The workers were followed 
from their first date of employment (beginning in 1947) until their date of death or 
until the study ended in 2008.  Standardized mortality ratios (SMRs) were 
calculated using the Minnesota population as the referent population.  The risk of 
a cancer death was evaluated using a time-dependent Cox proportional hazards 
(PH) model, which compared the workers’ exposure over time to the non-
occupationally exposed workers at the St. Paul location.  There were a total of 
2,979 identifiable deaths in the cohort, and of these there were 72 prostate cancer 
deaths, 48 pancreatic cancer deaths, 16 bladder cancer deaths, 24 kidney cancer 
deaths, 25 female breast cancer deaths, and 15 liver cancer deaths.  The SMR for 
prostate cancer deaths in the Chemical Division workers was 1.18 based on 16 
observed versus 13 expected deaths.  All cancer-specific hazard rations (HRs) 
using annual continuous exposure estimates were at or below no effect level with 
increasing exposure to APFO/PFOA.  The population was additionally divided 
into six exposure groups.  The HRs for workers showed an increase in the risk of 
a prostate cancer death with increasing exposure groupings compared to the St. 
Paul group [HR=1.22, (95% CI: 0.57-2.61), and HR=1.27 (95% CI: 0.30-5.28)], 
for the top two exposure groups.  These results were imprecise, but showed a 
dose-response relationship.   
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This study explored the risk of cancer mortality associated with age and 
intensity of exposure.  The findings show a non-significant elevated risk of cancer 
deaths in the highest exposure groups for cumulative exposure during age 40-49 
[HR=1.96, (95% CI: 0.67-5.68), and HR=1.51 (95% CI: 0.47-4.90)], for bladder 
and liver cancers respectively.  These results were imprecise and based on six 
bladder and seven liver cancer deaths. 
Previous studies of the Cottage Grove population have shown an increased 
risk of death from prostate cancer with increasing exposure to APFO/PFOA using 
qualitative exposure groupings (Gilliland and Mandel, 1993; and Lundin et al., 
2009).  Risk of death was determined based on workers’ job title and did not 
explore quantitative dose estimates from air measurement data, as was done in the 
current study.  In this study we evaluated risk based on worker-specific 
quantitative annual exposure estimates from a reconstruction of the inhalation 
exposure at Cottage Grove.  Prostate cancer results for the Chemical Division and 
top two exposure groups from the current study support the previous results.  The 
overall results for all cancers are inconsistent when evaluating the continuous 
exposure compared to exposure group rankings, with the exception of kidney 
cancer.  Kidney cancer was consistently below unity across all analyses, while the 
remaining cancers only show modest increases in risk based on few cases.  
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CHAPTER 1:  INTRODUCTION 
  
 Ammonium Perfluorooctanoate (APFO) is in a class of synthetic 
polyfluorinated chemicals—perfluorocarbons (PFCs)—used primarily as a 
processing aid in the production of fluoropolymers and fluoroelastomers.  APFO 
is an eight-chain fully fluorinated organic compound that is thermally inert and 
chemically stable.  In the presence of water and other liquids, APFO dissociates to 
perfluorooctanoate (PFOA) and the ammonium ion. In the late 1930s the 
controlled synthesis of PFCs became available with electrochemical fluorination, 
which made commercial production of APFO/PFOA possible (Simons and Bryce, 
1954).   It lacks affinity for fat, water and oil, (i.e., it is lipophobic, hydrophobic, 
and oleophobic, respectively) making it an ideal chemical surfactant.  The carbon-
fluorine bonds are extremely strong and resistant to decomposition.  APFO is a 
chemical intermediate used in many industrial and commercial products that 
require surface protection such as: carpets, textiles, electronics, cookware, paper 
and wood board surfaces because of its unique properties to repel water and oil 
(US EPA, 2005).  At the 3M facility in Cottage Grove, Minnesota, APFO was 
formulated as a polymerization aid used in the production of high-performance 
materials and other consumer products from 1947-2000—when the company 
began its phase out.   Production ended and was completely eliminated in 2002. 
Exposure to APFO/PFOA can occur from various environmental sources 
including: airborne dust, contaminated water and food, and contact with various 
consumer products including the degradation of other fluoropolymer-containing 
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 products (Paustenbach, 2007).  When ingested, inhaled or absorbed through 
dermal contact, APFO dissociates to the anion form [CF3(CF2)6COOH-NH3= 
CF3(CF2)6COO- + H+ + NH3]  of perfluorooctanoic acid (PFOA) inside the body.  
PFOA is the unconjugated metabolite measured in blood-serum samples of 
humans and other animals following exposure to APFO (Kuslikis et al., 1992).   
For many years PFCs were considered non-toxic because of their inert 
chemical and physical properties.  However, over the past decade there has been 
an increased focus directed towards evaluating the potential adverse human health 
impact, in part, due to biological monitoring results of APFO production workers 
showing PFOA-serum levels two to three orders of magnitude greater than the 
general public (Olsen and Zobel, 2007). With these markedly high blood-serum 
concentration findings in production workers, compared to the public, in 
conjunction with the observation that PFOA produces a large range of toxic 
effects in animals including: cancinogenisis, heptotoxicity, immunotoxicity, 
developmental toxicity and endocrine toxicity, it is possible that exposure may not 
be innocuous in humans (Biegel et al. 2001; Butenhoff et al., 2002; Griffith and 
Long, 1980; Kennedy et al., 2004; and Yang et al., 2001).  What is unknown is 
the level of exposure in humans that may put them risk of adverse health 
outcomes.  Considering the long chemical half-life of serum-PFOA in humans 
compared to animals, and the potential that some workers had high and/or long-
term chronic exposure, if there are health repercussions from exposure then it may 
affect APFO/PFOA chemical workers—putting them at a greater risk of adverse 
outcomes when compared to workers who were not directly involved in chemical 
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 production or when compared to the general population.  Consequently, there is a 
need to establish what the health impact of APFO/PFOA on humans is and what 
level of exposure would contribute to an increase in the risk of an adverse health 
outcome.    
  Investigators of two previous occupational mortality studies reported a 
positive association between working in the highest APFO/PFOA exposure group, 
of three groups, and dying from prostate cancer for chemical workers at the 3M 
Cottage Grove facility (Gilliland and Mandel, 1993 and Lundin et al., 2008).  This 
outcome was based on the internal comparison of exposed to non-exposed 
workers using qualitative exposure categories determined by job title.  However, 
when the standardized mortality ratios were estimated from the general Minnesota 
population compared to the entire working population, there was no observed 
risk.  Therefore, depending on the choice of referent population, results varied.   
  To elucidate potential health effects associated with APFO/PFOA 
exposure and the impact of exposure on the risk of death—specifically cancer 
mortality—we completed a quantitative exposure assessment.  The goal was to 
determine the amount of APFO/PFOA over time each worker was exposed to 
using occupational air monitoring data, professional input, and the workers’ 
sequence of job titles and locations throughout their career.  This was conducted 
with the workers at the Cottage Grove plant and their cancer mortality rates were 
compared to workers in St. Paul, who had a similar demographic background to 
Chemical Division workers, however this working population did not have direct 
APFO/PFOA occupational exposure.  Our study population included workers 
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 from the two 3M plants who worked for a minimum of one year over the course 
of more than half a century.  All Cottage Grove workers in our cohort have an 
exposure history profile that was created based on the exposure reconstruction—
which captured daily exposure levels categorized by job title, location and year—
from each employee’s work history records.  Our primary goal in the context of 
this research is to evaluate the risk of a cancer death that is associated with 
APFO/PFOA exposure in the workers by utilizing their updated exposure profiles 
with extended follow-up time.  We accomplished this by utilizing the individual-
level time-dependent exposure profiles and compared the rates of six a-priori 
cancer deaths and other health outcomes based on exposure levels.  In summary, 
we calculated the mortality rates using the following analyses: the standardize 
mortality ratios (SMRs) with Minnesota population-level data, hazard rate ratios 
based on exposure groupings and continuous annual exposure data, exposure 
during two decades, and finally the intensity of exposure with the referent 
working population as a sensitivity analysis. 
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 CHAPTER 2:  BACKGROUND AND SIGNIFICANCE 
 
 Ammonium perfluorooctonoate (APFO) is the primary salt of 
perfluorooctanoic acid (PFOA).  PFOA is globally distributed and has been 
detected in a variety of environmental media including surface water, air and soil 
samples (Yamashita et al., 2005 and Lau et al., 2007).  The presence of PFOA in 
blood sera found in the general public may arise from a combination of sources 
such as environmental contamination of water, air and food.  In addition, 
exposures can occur from the metabolic degradation of precursor compounds 
found in commercial and industrial products (Andersen et al., 2008).  PFOA is 
resistant to decomposition and bio-accumulates in humans and other animals—
with a residence time of several years in humans compared to weeks or less in 
animals.  In toxicological studies, animal models have shown an increase in the 
incidence of tumors and other adverse health outcomes at large doses (Biegel et 
al., 2001 and Kennedy et al., 2004).  Due to its bio-persistence, widespread 
environmental distribution, long human serum half-life and uncertain 
toxicological effects in humans, PFOA has become a public health concern 
among the scientific community and the public.  
 PFOA is one of many perfluorinated compounds (PFCs) released into the 
air, soil and water from production activities and from the breakdown of precursor 
chemicals.  It has been detected in both the Pacific and Atlantic oceans with a 
mean concentration of 439 picograms per liter (pg/L).  PFOA has also been 
measured in the atmosphere in close proximity to production facilities with 
concentrations ranging from 0.1–3.84 micrograms per cubic meter of air (µg/m3) 
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 (Yamashita et al., 2005 and Barton et al., 2006).  The ionic forms of PFCs are 
transported with ocean currents and the volatile, precursor PFCs (e.g., 
fluorotelomer alcohols, FTOHs) are transported in the atmosphere and later 
breakdown to form PFOA and other PFCs (Dreyer et al., 2009; and Stock et al., 
2007).  PFOA is mobile in soil and can leech into drinking water.  It bio-
accumulates in fish and other animal species (Houde et al., 2006).  The major 
non-occupational exposure pathway of PFOA comes from oral exposure 
including the consumption of contaminated water and food due to chemical 
migration of packaging, and indirectly from dust ingestion (Emmett et al., 2006; 
and Begley et al., 2005).   
  At this time there are no promulgated standards for PFOA in drinking 
water, consumer products, or for occupational exposures in the U.S.  However, 
the American Conference of Governmental Industrial Hygienists (ACGIH) has set 
guidelines for the threshold limit value (TLV) at 0.01 mg/m3 for workers who are 
exposed to APFO 40 hours a week, annually as the time weighted average (Miller 
et al., 2007).  PFOA is on the priority list to be evaluated for carcinogenicity by 
the International Agency for Research on Cancer (IARC) of the World Health 
Organization (WHO).  A formal review of the literature conducted by the U.S. 
EPA’s Science Advisory Board (SAB) suggested that PFOA is “likely to be 
carcinogenic to humans” (US EPA, 2006).  In addition to the occupational 
guidelines, in 2006 the U.S. EPA set an action level in drinking water at 0.5 parts 
per billion (ppb)—which was a sharp decrease from the 150 ppb level set in 2002 
(US EPA, 2006).  Furthermore, at the local level, in Minnesota the state health 
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 department lowered its health-based value in drinking water from 1.0 to 0.5 ppb 
(MDH, 2007). 
  In the early 1990s, scientists in 3M’s Medical Division began a voluntary 
program to collect and test the blood of workers for PFOA.  In 2000, 
approximately 70% of employees involved in APFO production participated in 
3M’s medical surveillance program.  The blood-serum PFOA concentrations were 
log normally distributed, and ranged from 7 ppb to 92 ppm (3M Final Report, 
2003b).  The same year 3M established a biological limit value (BLV) of 5 ppm 
(µg/mL) in the workers engaged in APFO production.  This BLV was based on a 
10-fold safety factor applied to sera concentrations that were associated with liver 
weight increases in a sub-chronic feeding study of cynomolgus monkeys 
(Butenhoff et al., 2002). 
 In the 1999-2000 National Health and Nutrition Examination Survey 
(NHANES) investigators collected US population based blood serum PFOA 
samples for the first time.  The serum-PFOA median value for the US population 
was approximately 5 ppb.  A second NHANES survey conducted in 2003-2004 
showed a downward trend in blood PFOA concentrations with a median value of 
3.9 ppb (Calafat et al., 2007). More recently, however, the Fourth National 
Exposure Report from March 2013 showed the serum-PFOA geometric mean 
concentration for the U.S. population was 5.21 ppb—an increase from the former 
survey (CDC, 2013).     
  Since the 1950s perfluoroalkyl chemistry—including ammonium 
perfluorooctanoate—has shown utility in surface applications by repelling oil- 
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 and water-based materials (Kennedy et al., 2004).  There are two main chemical 
processes used to manufacture APFO: electrochemical fluorination (ECF) and 
telomerization.  The ECF method was developed by Simons in 1941 (Simons and 
Bryce, 1954).  ECF reactions are fueled by electrical currents causing all the 
hydrogen atoms on the carbon backbone to be replaced with fluorine atoms using 
a low voltage, high current nickel anode (Lau et al., 2007).  The telomer process 
results in a linear APFO carbon chain, while the ECF process yields a partially 
branched chain (Kennedy et al., 2004).  Loveless et al. (2006) conducted a 
comparative study on mice and rats to evaluate the differences in toxicological 
properties for linear, linear/branched and branched APFO.  The overall response 
for both mice and rats was that the toxicity of the linear and linear/branched 
isomers was similar while the branched isomer was less toxic.   
Employees at the 3M Cottage Grove, Minnesota plant’s Chemical 
Division manufactured and processed APFO for more than fifty years.  The 
production included five stages: electrochemical fluorination, followed by the 
formation of a salt slurry mixture, the conversion to a salt cake, drying the cake, 
and finally packaging and shipping the ammonium salt (3M Final Report, 2003a).  
There was ample opportunity for exposure to the final product (APFO) in its 
particulate (ammonium salt) form and also to the vapor intermediate, PFOA, 
throughout the various phases of production.  Exposure occurred at low-dose 
levels from various daily work responsibilities/tasks and at high-dose levels—but 
short term—from less frequent spills and releases.  Routes of exposure primarily 
included inhalation exposure with some dermal exposure and possibly some 
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 incidental oral dust exposure.  The fabrication of APFO at 3M was phased out 
starting in May of 2000, and the final manufacturing and handling ceased in late 
2002.   
    In January of 2006, the U.S. Environmental Protection Agency and eight 
companies that produced APFO created a “2010/2015 PFOA Stewardship 
Program”.  These eight companies utilized APFO at lower levels compared to 
their high production years in the 1980s and 1990s.  Some have eliminated 
production completely within the U.S.  They all pledged to reduce their 
production and application by ninety-five percent in 2010 and work towards 
eliminating all uses by 2015 (US EPA, 2006).  Although these companies within 
the U.S. have pledged to phase out production of this bio-persistent chemical, 
currently other U.S. based and some international companies are involved in 
APFO production—and/or its application in the making of several industrial and 
commercial products.  It is unknown exactly what quantities of APFO/PFOA are 
released world-wide, however the estimate of global production from 2000-2002 
was between 5 and 6.5 million kilograms per year (Telomer Research Update, 
2002).   
Chemical, Physical and Toxic Properties 
 Ammonium perfluorooctonoate (CAS Registry No. 3825-26-1) is a fully 
fluorinated eight-chain carbon compound with an extremely low surface tension 
coefficient.  The carbon-fluorine bond is one of the strongest organic bonds in 
nature (Asakawa et al., 2008). It structurally resembles fatty acids with its 
hydrophilic carboxylate head and its hydrophobic and lipophobic fluorocarbon 
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 tail (Lemal, 2004).  It is a nonvolatile white powder at standard temperature and 
pressure, which can become readily airborne (Kennedy et al., 1986).  Its 
molecular weight is 431.10 g/mol, it has a vapor pressure of 7x10-5 mmHg at 
20°C and it sublimes (passes directly from the solid to gas phase) at 130°C.  It is 
nonflammable and is not readily degraded by oxidizing agents, or by strong acids 
or bases.  In the presence of aqueous media, APFO dissolves to form PFOA 
[CF3(CF2)6CO2NH4= CF3(CF2)6COOH + NH3]  (Griffith and Long, 1980). 
 Perfluorooctanoic acid (CAS registry number 335-67-1) has a molecular 
weight of 414.16 g/mol with a melting point of 59-60°C, and boiling point of 
189°C, at standard conditions.  PFOA is among the strongest acids known with a 
pKa= 2.5 (Olson C. and Andersen M., 1983).  PFOA is an intermediate in the 
production of the ammonium salt (APFO) and is produced as a mixture of 
branched chain isomers.   
  For clarification, when discussing human exposure and uptake of the 
chemical, APFO will be used to refer to all pre-absorption discussion and PFOA 
will be referenced after exposure has occurred and thus the chemical is no longer 
the ammonium salt, rather it is the dissociated anion of APFO, i.e. the metabolite 
found in biological media that is from APFO exposure.  In addition, in proceeding 
chapters APFO/PFOA will be utilized to show potential for exposure to both 
particulate and the vapor, respectively. 
  Several acute, sub-chronic and chronic studies have been conducted with 
various animal species and by different pathways of exposure (e.g., inhalation, 
dermal and oral exposures).  There are many recorded observed toxic effects in 
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 multiple species.  In acute toxicity studies the lethal dose for half of the animals 
(LD50) tested in a study by Glaza (1997) was greater than 500 mg/kg of body 
weight for male rats and 250-500 mg/kg for female rats.  Acute inhalation and 
dermal toxicity of APFO was tested in Sprague-Dawley rats and Hra(NZW)SPF 
rabbits, respectively (Glaza, 1995).  The inhalation dose applied to the rats was 
18.6 mg/m3 for one hour with no observed deaths.  The LD50 for dermal exposure 
to the rabbits was determined to be greater than 2000 mg/kg of body weight.  
APFO is a mild skin irritant and a moderate eye irritant in rabbits.  It exhibits a 
moderate acute oral and inhalation toxicity and mild dermal toxicity (Griffith and 
Long, 1980; Kennedy et al., 1986; and Kennedy et al., 2004).  The liver is the 
primary target for both acute and chronic effects of PFOA in rats (Griffith and 
Long, 1980) and in cynomolgus monkeys (Butenhoff et al., 2002).   
 PFOA is in a sub-class of peroxisome proliferators (PPs) that induce 
oxidative stress, which results in increased tumor formation associated with β-
oxidation (Reddy et al., 1980).  In rats, PFOA acts as an agonist for the 
peroxisome proliferator activated alpha-receptor (PPARα) signaling pathway.  
The interaction of PFOA with PPARα up-regulates several genes, which lead to a 
significant increase in hepatocellular tumors in rats.  A triad of tumors was 
observed including hepatocellular adenomas, testicular Leydig cell tumors, and 
pancreatic acinar cell tumors, after a lifetime of oral exposure in male Sprague-
Dawley rats (Biegel et al., 2001).  In a study by Yang et al. (2002), reductions in 
spleen and thymus weight were observed only in wild-type mice, not in PPARα-
null mice, suggesting that PPARα activation may be a factor in the observed toxic 
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 effects.  Likewise, PPARα-null mice do not exhibit the typical PP-mediated 
response of carcinomas.  However, PFOA may act as a cancer promoter in 
PPARα-null mice and cynomolgus monkeys and has been shown to cause 
hepatomegaly—an enlarged liver (Butenoff et al., 2002).   
  Non-carcinogenic toxic effects reported in animals include: liver and 
kidney-weight increases, decreased overall weight gain, alterations in lipid 
metabolism, uncoupling of oxidative phosphorylation, decrease in testosterone 
levels, increase in estrogen circulating hormones and a modest increase in total 
cholesterol (Griffith and Long, 1980; Haughom and Spydevoid 1992; and Sakr et 
al, 2007).  PFOA has been shown to induce mitochondrial proliferation in rats—
which may account for an increase in liver mass (Butenhoff et al., 2002).  
Inhibitory feeding behavior and delayed gastric emptying were seen in mice 
examined after they were given intraperitoneal injections of PFOA (Asakawa et 
al., 2008).  There are no known teratogenic effects and there is no evidence of 
deleterious reproductive effects from a two-generation reproductive study 
(Butenoff et al., 2004).  Data suggest that APFO is not genotoxic since it was not 
found to be mutagenic in the presence or absence of metabolic activation in the 
Ames test using five strains of Salmonella typhimurium (Griffith and Long, 
1980).  Yang et al (2001) reported on the immunotoxic effects of oral APFO 
exposure showing decreases in thymus and spleen weights noted in male mice.  
These changes have only been established in animal studies and it is unclear if 
these toxic effects are significant for humans.  
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 Pharmacokinetics 
Based on the results of several animal studies, there is no evidence that 
PFOA is metabolized in mammals (Kuslikis et al., 1992; and Vanden Heuvel et 
al., 1991).  APFO is rapidly and completely absorbed following inhalation and 
oral exposure—and to a lesser extent after dermal exposure.  After absorption, 
PFOA is distributed primarily to the liver, kidneys and plasma.  To a lesser extent, 
it is distributed to various tissues including the lungs, heart, skin, testes, muscle, 
fat and brain (Kennedy et al., 2004).  PFOA binds strongly to plasma and other 
proteins in the body with saturation of binding sites occurring at 30 mg/kg 
(Hanhijavri et al., 1988).  Covalent binding of PFOA was reported for proteins in 
liver, plasma, and testes of rats (Vanden Heuvel et al., 1992).  More recent data 
show that over 90% of PFOA is bound to blood albumin in the rat, monkey, and 
in humans (Han et al., 2003).  Biochemical changes reflect changes in hepatic cell 
morphology.  In rats, PFOA is a potent inducer of hepatic cytochrome P450, 
cytochrome P450 reductase and epoxide hydrolase (Pastoor et al., 1987).   
PFOA does not undergo de-fluorination and there is no evidence of phase 
two metabolism following a single dose (Ylinen et al., 1989).  There is evidence 
of enterohepatic recirculation—the circulation of bile from the liver to the small 
intestine and back to the liver—with the primary route of excretion occurring in 
the urine (Kennedy et al., 2004).  There are marked differences in the rate of inter 
and intra-species PFOA elimination.  In rats, differences in clearance rates 
between females and males were evaluated using 14C-PFOA intravenously 
administered.  Females excreted almost 100% of the administered dose within 24 
hours, whereas males excreted less than 25% in the same time frame (Johnson et 
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 al., 1979).  Male rats appear to be more sensitive to PFOA presumably due to the 
long half-life compared to the half-life in female rats; with half-lives of hours for 
females compared to days for males (Kennedy et al., 1986).  The rapid excretion 
found in female rats is due to an estrogen-dependent active renal tubular secretion 
mechanism of the organic ion transport system (Andersen et al., 2006).  This 
secretion system may be hormonally controlled since castrated male rats treated 
with estradiol have similar excretion rates as female rats (Ylinen et al., 1989).  
The biological half-life of serum-PFOA has been established for several 
species including rats, rabbits, mice, dogs and monkeys.  Rats have been studied 
extensively and as previously stated, the half-lives range from 5-10 days and 5-7 
hours for males and females, respectively (Ohmori et al, 2003; and Vanden 
Heuval et al., 1991).  The half-life in male and female rabbits was 5-7 hours after 
a single dose of 20 mg/kg; and the serum half-life of PFOA in male and female 
mice was 12 and 20 days, respectively.  The half-life in male and female dogs was 
three weeks and one week, respectively after an intravenous dose of 30 mg/kg 
(Hanhijarvi at al., 1988).  In a six-month oral dose study of cynomolgous 
monkeys, the half-life of PFOA in sera was reported to be approximately 20 days 
for males and 30 days for females (Butenhoff et al., 2002). 
Human half-life estimates are on the order of three to five years based on 
retired occupationally exposed workers (Olsen et al., 2007a).  Humans have a 
decreased ability to excrete PFOA compared to animals, which suggests the 
potential for ongoing low-level toxicity.  Traces of PFOA from production 
workers were found to remain at detectable levels long after cessation from work 
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 place exposures (Ubel et al., 1980).  The difference in half-lives between animals 
and humans is dramatic, and there appear not be significant sex differences in 
excretion rates for humans—unlike many other animals.  The closest animal 
model to humans (non-human primates) shows a half-life range of several weeks 
for monkeys compared to several years for humans.  When assessing risk to 
humans, scientists may be underestimating the long-term health-related impacts of 
APFO exposure. 
Toxic Effects 
 There is a large database of information related to PFOA toxicity.  It 
includes carcinogenicity, reproductive toxicity, developmental toxicity, 
immunotoxicity, hepatotoxicity, and mode of action studies.  The following 
information highlights data specific to these toxicities and provides study details 
that elaborate on the previous overview of APFO/PFOA toxicity: 
Carcinogenicity 
  PFOA has been found to act as a cancer promoter of liver tumors from a 
rat initiation-selection-promotion bioassay (Nilsson et al., 1991).  Investigators 
from two separate two-year feeding studies of rats evaluated APFO and its 
carcinogenic potential.  Biegel et al. (2001) administered a maximum dose of 300 
ppm to the test animals.  APFO was found to increase the incidence of benign 
hepatocellular adenomas, testicular Leydig cells, and pancreatic acinar-cell 
tumors at 300 ppm.  In a two year feeding study of female rats, an increased 
number of mammary fibroadenomas was observed in the PFOA-fed rats 
compared to the control group (Sibinski, 1987).   
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   Tilton et al. (2008) examined gene expression in an in-vivo trout cancer 
model to evaluate the potential of PFOA as a carcinogen in the absence of 
peroxisome proliferation—which may be more relevant to human health 
compared to other animal models due to the mode of action.  This chronic feeding 
study demonstrated that at a dose of 50 mg/kg/day, PFOA was a cancer promoter 
of the liver.  The tumor promotion was correlated with estrogenic signaling in 
trout, which was independent of the peroxisome proliferation mechanism of 
toxicity.   
Reproductive Toxicity 
  Butenhoff et al. (2004) studied male and female Sprague-Dawley rats 
given 0, 1, 10, and 30 mg/kg/day of APFO orally.  This was a two-generation 
study with the first generation dosed prior to mating, and their offspring dosed 
after weaning.  No adverse effects were observed in mating, fertility or natural 
delivery in either generation.  However, sexual maturation was delayed for the 
highest dosed group in the second generation.   
Developmental Effects 
  Midasch et al. (2007) showed that PFOA crosses the placental barrier after 
analyzing human maternal and cord blood samples taken from eleven mother-
infant pairs.  Similar effects of PFOA readily crossing the placenta in addition to 
being detected in breast milk have been found in Sprague-Dawley rats (Fei, 
2008). 
  The toxic effects of fetal development have been studied in rats and 
rabbits for both inhalation and oral exposures to APFO.  Pregnant rats were 
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 exposed to five dose-levels of APFO ranging from 0.14 -21 ppm.  Mean fetal 
body weight decreased for the fetuses of the surviving dams exposed to 9.9 ppm 
and higher concentrations of APFO (Staples et al., 1984).  In another 
developmental study, rabbits were given oral doses of 1.5, 5 or 50 mg/kg from 
gestation day six through day 18.  No evidence of fetus abnormalities was seen—
even at the highest dose group where the dams showed a reduction in maternal 
weight gain (Gortner, 1982).     
Immunotoxicity 
  In a feeding study of monkeys, both lymphoid tissue and bone marrow 
were found to be sites of histopathology.  The monkeys in the highest and second 
highest dosed groups had moderate hypocellularity of the bone marrow and 
atrophy of lymphoid follicles in the spleen and lymph nodes (Griffith and Long, 
1980).  Yang et al. (2001) conducted a dietary study of male mice for ten days.  
As previously stated, there were observed decreases in the thymus and spleen 
weights, and an increase in liver weight.  These effects were dose dependent.  In 
addition to these findings, PFOA was found to be immunosuppressive in the mice.  
Another study confirmed these findings and indicated that the toxic effects were 
related to the suppression of the immune mediated inflammatory response 
(Guruge et al., 2006).  Fairley et al. (2007) examined the effects of dermal 
exposure in mice and found an increased Immunoglobin E (IgE) response.  These 
results suggest that PFOA may be immunotoxic and that it may augment the IgE 
response to allergens.   
19 
 
 Hepatotoxicity  
  Griffith and Long (1980) studied male and female rats.  In this dietary 
study, there were statistically significant differences seen between the control 
group and the APFO fed groups.  The mean female and male liver weights, in the 
300 ppm and 30 ppm groups, were greater than the controls.  In a 90-day dietary 
study of rats, doses as low as 100 ppm (5mg/kg/day) for males and 1000 ppm 
(76.5 mg/kg/day) for females, showed a significant increase in liver weight and 
hepatocellular hypertrophy (Goldenthal, 1978).  Palazzolo (1993) studied male 
rats fed ad libitum a diet containing 1, 10, 30, and 100 ppm of APFO.  Mean body 
weight gains were significantly lower for the 100 ppm group compared to the 
control group.  Hepatic palmitoyl-CoA oxidase activity was significantly higher at 
the 30 and 100 ppm groups when compared to the control group. A lowest 
observed adverse effect level (LOAEL) was observed for the 10 ppm group. 
Mode of Action: PPARα activation and lipid metabolism 
 PFOA has been observed to activate the PPARα receptor, which acts as 
peroxisome proliferator (PP) in rodents.  PPARs are a structurally diverse group 
of nongenotoxic carcinogens (e.g., Trichloroethylene, is a solvent and a PP).  
They belong to a family of nuclear hormone receptors.  These are ligand-activated 
transcription factors that play a large role in lipid metabolism (Michalik et al., 
2006).  Prolonged exposure to PPs has been shown to increase the incidence of 
liver tumors in rats (Abdellatif et al., 1991).  The increase in liver tumors is 
thought to be from sustained oxidative stress and the regulation of cell 
proliferation and differentiation.  The effects of PFOA on PPARα-null mice were 
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 studied showing hepatomegaly—which suggested that PFOA might cause liver 
toxicity independently of PP (Yang et al, 2002).   
 Cook J. et al. (1991) conducted a set of experiments in rats.  The results 
showed that decreased testosterone levels were associated with PFOA treated rats, 
which resulted from altered steriodogenesis in the Leydig cell.    
 In rats and monkeys, PFOA has been shown to induce mitochondrial 
proliferation.  These effects may be associated with oxygen stress and apoptosis, 
as PFOA disrupts the inner membrane which affects respiratory functions (Keller 
et al., 1992 and Strakov and Wallace, 2002). 
 The mechanism of action of PFCs has been reported as mediated by the 
cell membranes.  PFOA has been suggested to alter cell membrane function 
through changes in fatty acid composition and oxidation status (Olson and 
Andersen, 1983).  PFOA has the ability to interfere with fatty acid metabolism 
and cholesterol synthesis in the liver (Haughom and Spydevold, 1992).  The 
serum cholesterol levels in the rats tested decreased by 50-70% after the initial 24 
hours of dosing.  Conclusions from this study indicate that the hypo-lipidemic 
effect was from the reduced synthesis of esterification of cholesterol in 
conjunction with the enhanced oxidation of the liver fatty acids.  In a study of 
workers, hormone levels were examined along with concentrations of PFOA 
(Olsen at al., 1998).  Serum cholesterol and triglycerides were positively 
correlated with blood serum-PFOA levels.  This is inconsistent with the animal 
data showing that increased levels of PFOA are related to decreased lipid 
concentration. 
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  Many of the results observed in the toxicological studies may not relate 
directly to humans, in particular the mode of action in humans is unknown.  
Animal toxicity is observed at relatively high doses of APFO/PFOA compared to 
what the general population is exposed to from the environment. Therefore the 
body burden is much lower outside the laboratory.  However, the length of time 
for the clearance of PFOA in humans is almost three-fold greater when compared 
to other animals. The absolute toxic properties and subsequent health effects on 
humans remain uncertain.  What may help clarify this uncertainty and make for a 
more justified extrapolation for the general population is to evaluate the varying 
levels of occupational exposure and the health outcomes seen in the current 3M 
study population using a quantitative exposure assessment. 
Preliminary Epidemiologic Studies 
U of MN: Cancer Mortality Among 3M, PFOS Workers in Decatur, 
Alabama 
 PFOA is related to a synthetic perfluorinated chemical, 
perfluorooctanesulphonly fluoride (PFOS), which was manufactured at another 
3M location in previous decades (Alexander et al., 2003).  Study investigators 
conducted a retrospective cancer mortality study based on three levels of exposure 
to PFOS.  The findings showed a potential association between exposure and 
adverse health outcomes—specific to bladder cancer.  This was based on only 
three bladder cancer cases and the authors stated the possibility of a chance 
finding could not be ruled out. 
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 U of MN: Initial Mortality Study of Workers Employed at the 3M Cottage 
Grove Facility 
A retrospective mortality study was conducted with employees at the 3M 
Cottage Grove plant by investigators at the University of Minnesota (Gilliland 
and Mandel, 1993).  This was the first study to look at workers’ exposures to 
APFO and evaluate any potential health outcomes associated with exposure.  This 
cohort of workers included 2,788 males and 749 females who were employed for 
a minimum of six months between the years 1947-1984.  The employees were 
placed into two groups; the first group consisted of workers in the Chemical 
Division, and the second group consisted of employees who never worked in the 
Chemical Division.  Vital status was ascertained and death certificates were 
obtained from the National Death Index (NDI).  The records were searched for the 
contributing cause of death.  Estimates of APFO exposure were based on job 
history and worker status of ever versus never employed in the Chemical 
Division.  The total time spent working in the Chemical Division provided the 
cumulative exposure metric for analysis.  Standardized mortality ratios were 
adjusted for covariates and compared to the state of MN and US general 
populations.  Age at first employment was positively, but not statistically, 
associated with prostate cancer death.  The statistically significant observed health 
outcome was for employees who worked in the Chemical Division.  They had an 
increased risk of dying from prostate cancer when compared to the MN 
population.  Men had a three-fold increase of prostate cancer with ten years of 
employment in the Chemical Division.  The authors were cautious in any over 
interpretation of the outcome based on the small number of cancers, but suggested 
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 that if the excess in mortality from prostate cancer was related to APFO that it 
may be through endocrine alterations.   
  Gilliland and Mandel (1996) studied 115 occupationally exposed workers 
in a cross-sectional study design to evaluate cholesterol, hepatic enzymes and 
lipoproteins in association to APFO exposure.  This was an ancillary study from 
their primary mortality study conducted to evaluate a sample of the entire worker 
population previously described.  The researchers observed a positive association 
for increased serum-PFOA levels with an increase in liver enzymes and 
hepatocyte necrosis, suggesting irreversible cell damage.  Serum-PFOA was 
positively associated with estradiol and thyroid stimulating hormone, while it was 
negatively associated with free testosterone.  The authors stated that these results 
suggest that PFOA affects male reproductive hormones.   
U of MN: Follow-up Mortality Study of Workers Employed at the 3M 
Cottage Grove Facility 
A study was conducted as a follow-up to the initial mortality study to 
assess the death experience of employees at an ammonium perfluorooctanoate 
production facility (Alexander, 2001; and Lundin et al., 2008).  The purpose of 
this study was to determine if occupational exposures to APFO were related to the 
workers’ mortality experience.  The cohort was enumerated starting in 1947 
through the end of 1997.  There were 3,993 eligible workers who met the 
minimum criteria, which was one year of employment.  Data records were 
abstracted from 3M and exposure to APFO was calculated based on job titles that 
were independently reviewed by a panel of experts from 3M (including veteran 
workers and industrial hygienists).  The job titles recorded for each worker were 
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 static—meaning the analysis was based on only one job title per employee.  Three 
categories of exposure were evaluated in this cohort (definite, probable, and 
none).  The death experience of this occupational group was determined through 
2002 and standardized mortality ratios (SMRs) were estimated for all cause and 
cause-specific deaths.  The referent group for the SMRs was the state of 
Minnesota population.  There were 807 deaths reported and the SMRs for all 
causes of death and for cancer mortality were 0.8 (95% CI 0.7-0.9) and 0.9 (95% 
CI 0.8-1.0), respectively.  Also, analyses included a Cox proportional hazard 
regression model to estimate cancer risk with an internal referent population.  
Workers who were categorized as part of the high or moderate exposure group, 
compared to the low exposure group, had an elevated risk of death from prostate 
cancer (HR=7.0, 95% CI 1.4-18.6 and HR=3.0, 9.5% CI 0.8 -11.0, respectively).    
The results indicated no association between APFO exposure and cancer when 
using the general population as the reference group; however, there were findings 
associated with an elevated risk for prostate cancer death for both definite and 
probable exposure groups when compared to an internal non-exposed group.    
U of MN: Cancer Mortality Among 3M, Oil, Chemical and Atomic Workers 
Union, Local 6-75 
A retrospective mortality study was conducted by the University of 
Minnesota’s School of Public Health.  It included workers from the 3M oil, 
chemical, and atomic workers union at the St. Paul location from 1947 through 
the end of 1992.  The employees were divided into six job groups based on 
department numbers and there were five activity classifications included in each 
individual’s record.  Vital status was determined through the National Death 
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 Index (NDI) and also from drivers’ licenses records, MN and WI death 
certificates and active tracing to determine residential status of the workers.  
Cause and date of death were recorded for all individuals. The analysis of this 
mortality study included 3,995 men and 564 women and SMRs were calculated 
based on the state of MN and the seven county metropolitan area populations.  
The main findings included an elevated risk of stomach cancer in female 
employees and large intestinal cancer in male production tape employees. 
Summary 
 
 Overall, many studies—both animal and occupational studies—have been 
conducted in order to improve the level of understanding regarding the health 
effects of APFO/PFOA related to human health.  The ACGIH rates APFO as a 
confirmed animal carcinogen, with unknown relevance to human health.  
Carcinogenic endpoints observed in animal studies that may impact human health 
include: cancers of the liver, pancreas, testicles, breast, and thyroid gland 
(Butenoff et al., 2004, and Biegel et al. 2001).  In the aforementioned 
occupational mortality studies of APFO exposure have shown an increase in risk 
of death from prostate cancer and bladder cancer, albeit with few workers (Lundin 
et al., 2008; and Alexander et al., 2003). 
 Globally, it remains that production is ongoing, exposure is wide-spread and 
the human health endpoints related to various levels of exposure are uncertain.  In 
this research, our aim was to assess the levels of exposure in our working cohort 
over time in relation to their mortality experience in order to better understand the 
long-term potential health impact of the chemical on human health.     
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 CHAPTER 3:  RESEARCH DESIGN AND METHODS 
Specific Aims 
 
The over-arching goal for this area of research was to evaluate health 
outcomes from exposure to ammonium perfluorooctanoate (APFO) and 
perfluoroocatanoic acid (PFOA).  Specifically, the purpose of this study was to 
examine the relationship between occupational exposure to APFO/PFOA and the 
risk of death from six a priori selected cancers; bladder, breast, kidney, liver, 
pancreatic and prostate.  To achieve this goal, our plan was to evaluate cancer 
mortality from an occupational cohort with employees who had a broad range of 
APFO/PFOA exposure estimates spanning more than fifty years.  The exposure 
estimates were completed by conducting a historical exposure reconstruction, 
using air measurements and calculating daily inhalation values for workers at an 
APFO/PFOA manufacturing plant.  The exposure values assigned to each worker 
were based on their job title, location and date of employment.    To ascertain the 
risk of cancer mortality we explored the relationship between the time-dependent 
cumulative estimates of APFO/PFOA exposure by linking individuals to death 
records and their mortality experience.  This was completed using a retrospective 
occupational cohort consisting of two 3M locations.  The workers completed a 
minimum of one year of work from their start date through the end of 2008.  The 
following specific aims were addressed in pursuit of our long-term study goals: 
1. We established a complete occupational cohort of all eligible employees 
from two 3M locations from 1947-2008; the Cottage Grove facility 
(APFO/PFOA exposed workers) and the St. Paul plant (non-
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 occupationally exposed workers).  To meet the eligibility criteria the 
employees must have worked for a minimum of one calendar year as of 
December 31st, 2008. 
2. We developed a work history profile for each eligible employee to include 
specific job titles and department combinations in addition to all job start 
and end dates for each unique combination.  This was carried out by 
updating and standardizing job titles, building on a previously enumerated 
work history data set of Cottage Grove workers, which ended in 1997.   
3. We ascertained updated mortality records from the National Death Index 
(NDI) for all eligible workers to record cause and date of death through 
the end of 2008.  
4. We constructed an APFO/PFOA-exposure data matrix (EDM) for the 
period of 1947-2008 (starting when APFO was first synthesized) based on 
air sampling data, and professional input for all job titles by year of 
exposure at the 3M Cottage Grove facility.  An example of an EDM for a 
few workers is provided (Figure 1). 
5. We developed a time-dependent exposure profile for each Cottage Grove 
worker in the study population based on exposure estimates from the 
EDM linked to job title, dates worked per job title and department 
location.  The EDM was used to create each individual’s unique exposure 
profile based on the inhalation in mg/m3 of APFO/PFOA.  Examples of 
workers are provided (Figure 2). 
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 6. We calculated two annual estimates of exposure to APFO/PFOA based on 
the sum of exposure and the biologically effective dose for each worker in 
milligrams (mg) of exposure and placed workers into categories of 
exposure. Two exposure models were used.  The first model was a 
standard cumulative exposure model and the second was a clearance 
weighted cumulative model—used to account for the elimination of 
serum-PFOA in addition to exposure over time (Figure 3).   
7. We evaluated cancer mortality risk based on cumulative exposure, during 
two distinct decades, and exposure intensity.  Both time-dependent dose 
estimates were evaluated (i.e., the cumulative and the clearance weighted 
estimates in mg).  
8. We determined the association between the estimated APFO/PFOA 
exposures and risk of death from cancer for bladder, breast, kidney, liver, 
pancreatic, and prostate a priori specific cancers.  We evaluated 
uncertainty by the re-parameterization of exposure groupings. 
 
The three central hypotheses for this study to address the specific research 
goals included:  
1. Occupational exposure to APFO/PFOA is associated with an increased 
risk of cancer; specifically bladder, breast, kidney, liver, pancreatic, 
prostate, and all-cause cancers. 
2. Risk of cancer is associated with age at exposure to APFO/PFOA.  
36 
 
 3. Risk of cancer is associated with the intensity of exposure to 
APFO/PFOA. 
Collaboration 
 
This study builds on previous work conducted by the Division Of 
Environmental Health within the School of Public Health at the University of 
Minnesota in collaboration with the 3M Company of Minnesota.  3M personnel 
provided historical employment records, information on the manufacture of 
Ammonium Perfluorooctanoate and the jobs that were involved in its production 
and handling.  They also provided historical air monitoring data. This 
collaboration served the primary goal of this research, which was to evaluate the 
health of APFO/PFOA exposed workers by utilizing quantitative dose estimates 
with mortality data. 
Research Overview 
 
 For more than half a century 3M workers manufactured, packaged and 
shipped APFO to various locations.  These workers had the opportunity for a wide 
range of exposures—depending on job location and job tasks—which varied over 
time.  The effects of APFO/PFOA exposure on human health were studied in the 
employees of the Cottage Grove, 3M facility using a retrospective cohort design. 
Previously, two populations of 3M employees from the Cottage Grove and St. 
Paul Minnesota plants were enumerated by University of Minnesota researchers 
in the Division of Environmental Health Sciences, School of Public Health.  The 
work history of these two groups was combined and updated with eleven 
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 additional years (1998-2008) of employment information to create one large 
cohort.  This cohort includes workers with and without occupational exposure to 
APFO/PFOA.  Workers at the St. Paul plant had no direct exposure to 
APFO/PFOA and the Cottage Grove workers had a wide range of annual 
exposure estimates.  More than half of the workers at the Cottage Grove facility 
were exposed to APFO/PFOA at some point during their work history by means 
of direct or indirect exposure.  The remaining workers had estimates of only 
background exposure.  All workers were placed into exposure groups after 
completing our comprehensive exposure reconstruction and based on the 
individual’s exposure profile created from linking their job history to exposure 
estimates from a newly created exposure data matrix.   
 All cause and cause-specific cancer mortality rates were compared among 
the referent and the exposure groups within the working population.  
Additionally, the workers’ continuous exposure estimates were evaluated to 
assess the risk of a cancer death.   Standardized mortality ratios (SMRs) were 
calculated for the cohort using the Minnesota state population reference rates.  
The hazard rates for the APFO/PFOA exposure groups were compared to the 
referent group—St. Paul workers.  The hazard ratios (HR) and odds ratios (OR) 
along with the 95% confidence intervals (CI) were calculated using time-
dependent Cox proportional hazard ratios and logistic regression models (Breslow 
and Day, 1987).  The Cox regression analyses were completed using the PHREG 
procedure in SAS 9.2 (SAS, 2011).  The HR and OR were stratified by gender 
and adjusted for first year of employment. 
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  The final cohort included 9,027 current and former 3M workers whom had 
up to 59 years of follow-up time.  Cancer rates for all-cause cancers in addition to 
bladder, breast, kidney, liver, pancreatic and prostate cancer were ascertained and 
the mortality rates of the exposed groups were compared to the St. Paul workers.    
Study Population 
 
We included all workers with a minimum of one year of employment at 
the 3M Cottage Grove and St. Paul locations beginning in 1947 through the end 
of follow-up, either date of death or December 31st, 2008 when the study ended.  
There were a total 4,668 workers from Cottage Grove and 4,359 workers from the 
St. Paul plant who met our minimum eligibility requirement.  Worker’s mean age 
at first and last employment was 30 and 44 years, and 29 and 49 years for St. Paul 
and Cottage Grove plants, respectively.  Females represented only 12% of the St. 
Paul group compared to 20% of Cottage Grove workers.  St. Paul workers on 
average were employed on average six additional years, 20 years, compared to the 
average number of years, 14 years, for all Cottage Grove employees. There were a 
total of 323,456 person-years for both locations.   
The Cottage Grove campus was divided into the Chemical and Non-
Chemical Divisions, with APFO/PFOA production limited to the Chemical 
Division.  The workers were initially categorized in either the Chemical or Non-
Chemical Division based on the department they worked in—some worked in 
both Divisions.  There were a total of 121 departments at the Cottage Grove 
facility and 23 were part of the Chemical Division.    More than half of all Cottage 
Grove workers held a minimum of one job in the Chemical Division at some point 
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 during their work history.  More males were represented in the Chemical Division 
(87%) compared to the workers in the Non-Chemical Division (72%).  Workers 
who only worked in the Chemical Division, on average, worked fewer years 
compared to all Cottage Grove workers, 11 and 15 years respectively.   
We did not have data on race or ethnicity; however, from personal 
correspondence/ retired employees (and as reported in the most recent mortality 
analyses by Lundin et. al) the population at both locations was predominately 
Cuacasion—which is consistent with state and county level data reported by the 
US Census Bureau (US Census Bureau; Quick Fact Sheet, MN).   
Data Collection 
 
 The human resource records were evaluated for work history information.  
Data from all workers with more than 365 days of cumulative employment at the 
Cottage Grove and St. Paul locations were abstracted.  For each employee, all 
unique combinations of job title, job department and dates of employment were 
recorded.  Job titles were standardized based on professional input after a 
thorough assessment of job responsibilities per job title. 
 The exposure data were obtained from more than 800 air measurements.  
Expert judgment was provided regarding the amount of time spent working with 
APFO/PFOA on a daily basis by specific job title, location and year of 
employment.  The final exposure values for the exposure data matrix (EDM) were 
calculated using the amount of time spent working with APFO/PFOA in 
conjunction with the air measurements to provide daily time-weighted averages 
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 (TWAs).  These TWAs were summed for each employee to provide a unique 
exposure history profile. 
 Date and cause of death were recorded from national data for all deceased 
cohort members using the National Death Index (NDI).  The cause of death for 
each person was coded by a certified nosologist using the International 
Classification of Disease (ICD) revision codes in effect at the time of death—the 
most current being the 10th revision. 
Data Analysis 
 
 The goal of this research was to evaluate the risk of death from cancer as a 
result of occupational exposure to APFO/PFOA.  The outcomes of interest 
included cancers of the bladder, breast, kidney, liver, pancreas and prostate within 
the 3M worker population at the Cottage Grove and St. Paul, Minnesota locations.  
We attempted to control for confounding with the aid of a causal model (Figure 
4).  The following three hypotheses were addressed: 
Hypothesis 1: Occupational exposure to APFO/PFOA is associated with an 
increased risk of cancer mortality; specifically bladder, breast, kidney, liver, 
pancreatic, prostate cancers. 
To evaluate the risk of death based on the worker’s exposure level we 
calculated the amount of person-time for each worker and estimated the hazard 
ratio using the time-dependent exposure estimates from two exposure models.  
Specifically, we modeled the relationship between the level of exposure of 
APFO/PFOA and the occurrence of a cancer death event using a time-dependent 
Cox proportional hazard regression model.  The hazard ratios (HRs) and 95% 
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 confidence intervals (CIs) were estimated by comparing the rates between the 
exposure groups (using both estimates of exposure from the two models 
independently) for the Cottage Grove workers and the St. Paul workers as the 
non-exposed referent group.  To account for cancer latency, we lagged the models 
by ten years.  In addition, we calculated the standard mortality ratios (SMRs) 
using the state of Minnesota death rates comparing both the Cottage Grove 
workers and the St. Paul works to the state population.  We controlled for year of 
entry into the cohort. 
Hypothesis 2: Risk of a cancer death is associated with age at exposure to 
APFO/PFOA.  
We calculated the risk of a cancer death based on the cumulative and 
clearance weighted exposure estimates during two decades.  This included 
estimates for the fourth and fifth decades of life.  We modeled the relationship 
between the level of exposure and the cancer events using a Cox PH regression 
model and the hazard ratios (HRs) and 95% confidence intervals (CIs) were 
estimated while controlling for year of entry into the cohort.   
Hypothesis 3: Risk of a cancer death is associated with the intensity of exposure 
to APFO/PFOA. 
To evaluate workers’ risk of death based on differences in their intensity 
of exposure (i.e., how quickly they reached a relatively low, medium, or high 
exposure estimate) we used dose-rate parameters as a measure of intensity.  We 
evaluated cancer death for each dose-rate group compared to the referent group, 
stratified by “total years worked” categories.  We calculated the odds ratios (ORs) 
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 and 95% confidence intervals (CIs) to estimate the probability of death from 
cancer based on the dose-rate level using a logistic regression model, controlling 
for year of entry into the cohort and gender.   
Sensitivity Analysis 
 
To account for the effects on the direction and magnitude of our risk 
estimates from bias and potential confounding, we evaluated risk after re-
parameterizing the exposures for the workers using various exposure 
classifications.  We explored workers risk of death by the redistribution of 
exposure groups.  We estimated the hazard ratios (HRs) using the time-dependent 
Cox proportional hazard models.  Finally, we explored workers who had similar 
final cumulative estimates of exposure and evaluated their risk of death after 
placing these workers in dose-rate groupings.  This was explained in the 
aforementioned intensity-exposure and risk of death hypothesis. 
Bias Evaluation 
 
Information Bias 
To ensure the validity of any epidemiological study—including 
occupational studies—it is important to account for potential systematic errors in 
the assignment of exposure and health outcomes.  The data for the EDM that we 
reconstructed was a rigorous process of utilizing available air measurements of 
APFO and PFOA in addition to the professional input of former 3M employees 
who knew the production process and exposure scenarios.  A structured 
evaluation of the amount of time spent working directly and indirectly with 
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 APFO/PFOA was a key determinant to calculate the exposure estimates for all 
employees in order to decrease or prevent bias.  The assignment of exposure for 
each worker was based on their unique work history and the sum of the daily 
TWAs for their profile.  This was all conducted in order to reduce the potential for 
exposure misclassification and the potential for information bias. 
The chance of information bias from the health outcomes—specifically, cancer 
deaths—is minimal due to our data collection of outcomes recorded using the 
NDI data.  Vital status is recorded through the national database and records 
provide the cause and date of death verified by certified nosologists with the ICD 
codes from the revision in effect at the time of death. 
Selection Bias 
 In the current study selection bias was not of primary concern.  This is due 
to the fact that we compared the exposed population (Cottage Grove workers) to a 
cohort of 3M workers with a similar socioeconomic status (SES).  To the best of 
our knowledge, the St. Paul workers were similar to the Cottage Grove workers in 
every way except with regards to the exposure of interest.  This may be most 
relevant when comparing the Chemical Division workers to St. Paul workers—as 
both populations were production workers (albeit working with distinctly 
different chemicals).  This is a key component to reducing selection bias. 
Human Subjects’ Protection 
 All work performed was approved by the University of Minnesota’s 
Institutional Review Board (IRB).  This was a follow-up cancer mortality study 
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 with minimal or no risk to the subjects.  The IRB 3M Cancer Study was 
#0809S47221. 
As stated, potential risks were negligible and the work history records with 
personal identifying information were kept in encrypted files on a secure 
password protected computer server.  Each participant was assigned a unique 
study identification number and the personal identifying information was kept 
separate from other study records.  Access to this server was limited to specific 
internet provider addresses. 
Summary 
 
Results from two previous mortality studies of 3M Cottage Grove workers 
showed a higher than expected rate of prostate cancer deaths in employees with 
expsoure to APFO compared to the employees with no known expsoure.  In 
addition to this observed outcome, several animal studies have documented 
adverse health outcomes of expsoure to APFO/PFOA including an increase in 
cancer of the liver, Leydig cells, and pancreatic acinar cells.  Other toxic 
endpoints from animal studies have shown an increase in liver and thymus 
weights, altered lipid metabolism, decreases in body weight, and endocrine 
effects.  This research focused on understanding the potential health effects of 
occupational exposure to APFO/PFOA by using the workers’ updated exposure 
profiles, derived from an in-depth exposure assessment, and evaluating the risk of 
a cancer death from six a-priori  and other health outcomes based on the time-
dependent exposure estimates of the workers. 
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Figures and Tables 
 
Figure 1. 
  
 
Exposure Data Matrix: Daily TWAs in mg/m3 of APFO/PFOA Exposure by Job Title, Department, and Year 
 
DEPT YEAR 
Administrative 
Assistant Analyst Chemist Custodian Engineer Manager  
Process 
Engineer Supervisor 
MMM 1954 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 
MMM 1955 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 
MMM 1956 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 
MMM 1957 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 0.00001 
MMM 1958 0.000015 0.000015 0.000015 0.000015 0.000015 0.000015 0.000015 0.000015 
MMM 1959 0.000015 0.000015 0.000015 0.000015 0.000015 0.000015 0.000015 0.000015 
MMM 1960 0.00002 0.00002 0.00002 0.00002 0.00002 0.00002 0.00002 0.00002 
MMM 1961 0.00002 0.00002 0.00002 0.00002 0.00002 0.00002 0.00002 0.00002 
MMM 1962 0.000025 0.000025 0.000025 0.000025 0.000025 0.000025 0.000025 0.000025 
MMM 1963 0.000025 0.000025 0.000025 0.000025 0.000025 0.000025 0.000025 0.000025 
MMM 1964 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 
MMM 1965 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 
MMM 1966 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 
MMM 1967 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 0.00003 
MMM 1968 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 
MMM 1969 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 
MMM 1970 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 0.00004 
MMM 1971 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 
MMM 1972 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 
MMM 1973 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 
MMM 1974 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 
MMM 1975 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 
MMM 1976 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 0.00005 
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Figure 3. APFO Exposure Equations: Cumulative and Clearance-Weighted 
 
In the equations below the estimated dose is in milligrams (mg), j refers to the specific year of exposure, 
 n is number of years worked, i is the ith worker, and k is the elimination constant, and is equal to 
 ln 2/T1/2. 
 
 
 
Potential Cumulative Dose (PCD) estimate of body burden in mg: 
PCDi =  ∑ni j=1  Eij 
 
Cumulative Clearance Weighted Dose (CCWD) estimate of body burden in mg: 
CCWDi =  ∑ni j=1 { >(CCWDj-1) or ( Eij ) *(e-k)} 
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Figure 4.  Directed Acyclic Graph: Prostate Cancer 
 
 
 
 
 
  
  
50 
 
   
51 
 
CHAPTER 4:  OCCUPATIONAL EXPOSURE TO 
AMMONIUM PERFLUOROOCTANOATE: AN INHALATION 
EXPOSURE RECONSTRUCTION EVALUATING TWO TIME 
DEPENDENT MODELS 
 
 
Workers at a chemical production facility in Cottage Grove, Minnesota 
manufactured ammonium perfluorooctanoate (APFO) for over fifty years.  
Employees who were directly involved in the development of APFO had potential 
for high-level exposure compared to non-production employees.  Other Chemical 
Division and Non-Chemical workers had potential for indirect, lower exposures to 
APFO.  The overarching goal for this paper was to reconstruct the APFO 
exposure history for all eligible employees and estimate each worker’s exposure 
over time.  Specifically, the purpose was three-fold: To demonstrate the methods 
used to build a facility-wide exposure data matrix; to display the range of 
exposures over time; and to explore exposure misclassification.  A primary 
limitation of some occupational studies is the choice of exposure model to reflect 
a time-dependent biological dose that represents true body burden.  To address 
this limitation we calculated a daily time weighted average (TWA) of APFO in 
milligrams per cubic meter (mg/m3) using historical air measurements for each 
worker catalogued by job title, location and year of employment.  Next, we used 
two exposure models to estimate time-dependent dose in milligrams (mg)—a 
standard cumulative model that describes the potential cumulative dose (PCD), 
and a cumulative clearance weighted dose (CCWD) model to account for 
retention and elimination of serum-PFOA.  We placed workers into one of six 
exposure groups using orders of magnitude to define the groups.  The daily TWA 
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 of inhalation exposure for all workers in the Non-Chemical Division ranged from 
1 x 10-8 to 1 x 10-5 mg/m3.  In the Chemical Division the range was up to five 
orders of magnitude greater.  For production workers within the Chemical 
Division, the daily exposure ranged from 0.001 mg/m3 to 0.379 mg/m3.  Overall, 
when comparing the two annual estimates we found workers who were most 
susceptible to potential misclassification were individuals assigned to the middle 
to high-dose groups and in their later years of life.  The exposure models and 
annual estimates provide options to examine specific assumptions about time 
related exposures, chemical retention and elimination, and disease onset.  
INTRODUCTION 
 
Perfluoroctanoic acid (PFOA), an eight chain fully fluorinated carboxylic 
acid, is a synthetic chemical surfactant with broad commercial and industrial 
application.  Its primary salt, ammonium perfluorooctanoate (APFO), was 
manufactured via electrochemical fluorination for more than fifty years at a 3M 
Cottage Grove facility in Minnesota.  Employees who worked in chemical 
production had potential for significant exposure to both PFOA and APFO 
primarily through inhalation.  Two mortality studies of this manufacturing cohort 
have been published in peer-reviewed literature.  The original retrospective cohort 
included 3,537 workers who were employed for a minimum of six months 
between 1947 and 1983.  Exposure categories were based on work history records 
of ever or never working in the Chemical Division of the plant (Gilliland and 
Mandel, 1993).  Lundin et al. updated the employment and mortality experience 
through 1997 to include a total of 3,993 workers.  The investigators classified 
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 exposure by three categories based on the worker’s job title and department 
combination: 1) definite exposure, 2) probable exposure, and 3) non-exposed 
(Lundin et al., 2009).  These classifications were combined with duration of 
employment for a weighted cumulative exposure.  Both studies reported an 
association between increasing exposure and death from prostate cancer, but the 
findings were dependent on the choice of referent population and statistically 
unstable.  A noted weakness in these studies was the limited nature of the 
exposure model.    
Historical exposure reconstruction, accounting for timing and intensity of 
exposure, is a critical step to understanding how exposure is related to long-term 
health outcomes, including cancer (Nieuwenhuijsen et al., 2006).  Occupational 
studies frequently rely on work history information to evaluate cumulative 
exposure, but less frequently evaluate time varying exposures related to health 
outcomes.  When analyzing the amount of chemical exposure and the likelihood 
of it being causal for a specific health outcome, it is essential to determine time-
varying dose estimates.  Workers may often have a similar cumulative exposure 
estimate at the end of their career, but may have a different risk of disease because 
of variable exposure scenarios over time.  Their real body burden may be affected 
by variables such as intensity of the exposure, time since last exposure and 
chemical retention and elimination from the body—all factors that are not always 
part of a standard exposure assessment.   In the most recent 3M mortality study, 
Lundin et al. (2009) stated that the use of duration of employment, instead of the 
range of exposure estimates that vary with calendar time, may have potentially 
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 contributed to some exposure misclassification.  It is possible that some workers 
who had job titles in the “probable” exposure category had short but intense 
exposures.  These workers, therefore, may have had a body burden similar to 
workers in the “definite” exposure group who had sustained, low dose exposures.  
The exposure categories captured a single job title, whereas many workers 
switched job titles—and therefore different levels of exposure—over time.  The 
current study captures exposure using quantitative estimates of exposure based on 
job title changes throughout each employee’s career. 
As part of an ongoing cancer incidence study and mortality update, the 
goal of this research was to develop a quantitative exposure metric that closely 
reflects body burden.  The exposure models will estimate cumulative and time-
varying exposure to APFO in this cohort.  
METHODS 
 
This section describes our approach to: 1) estimate the daily exposure for 
each worker using air measurements, production records, and professional input; 
2) develop exposure data matrices (EDMs) for each department in the Chemical 
Division based on job title, job location and year; 3) calculate quantitative 
exposure profiles for each worker in our cohort by linking work history records 
and the EDMs; and 4) display and evaluate two time dependent exposure profiles 
at the worker and cohort level. 
Study Population 
 The cohort included all workers employed at the Cottage Grove 3M plant 
for a minimum of one year of employment between 1947 through 2008 
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 (N=4,668). The Cottage Grove campus was divided into Chemical and Non-
Chemical Divisions, with APFO production limited to the Chemical Division. 
Within the Chemical Division a few departments were directly involved with the 
production of APFO and these changed over time.  Other departments may have 
had some involvement with APFO, but were not the main production sites.  The 
APFO chemical group locations were verified by reviewing company production 
records and with input from former employees.  
Production Process  
 The production of APFO was a multi-step process that included many 
tasks with various opportunities for workers to be exposed.  Inhalation exposure 
occurred from both the acid vapor and ammonium salt particulate phase during 
regular production duties and other less frequent responsibilities such as cleaning 
equipment, changing filters, and quality control checks.  Production workers had 
the potential for high-level exposure during rare events such as incidental spills, 
filter clogs and dust releases.  Low-level continuous exposure to APFO occurred 
from working in the general production environment without direct involvement 
in chemical production. 
The manufacture of APFO initially began in a small chemistry pilot plant 
in the late 1940s and expanded to an entire building with four main areas starting 
in 1951. The production process evolved over time including changes in 
equipment and volume output.  It increased steadily by decade until the 1980s 
when production fell from approximately 60,000 to 2,000 pounds per year.  In the 
1990s there was sharp increase until the end of production in 2002 (Table 1).  
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 The production process included the following steps: electrochemical 
fluorination, stabilization, fractionation, distillation, purification, the addition of 
ammonium, drying, and packaging the final product.  Electrochemical 
fluorination (ECF) reactions took place in the Cell Room.  The ECF reactions 
were conducted with the use of electrical currents that replaced all of the 
hydrogen atoms with fluorine atoms by adding hydrogen fluoride (HF).  HF was 
added to the eight-chain carbon compound inside 1,000 gallon stainless steel cells 
with encapsulated metal plates.  The material was piped through a closed system 
from the Cell Room to the reactors in the Kettle Room where the 
perfluorooctanoic acid (PFOA) was fractionated by separating out the eight-chain 
carbon compound.  PFOA was purified after high and low vapor pressure 
constituents were boiled off from the mixture by charging, distilling, and draining 
the material.  After the acid was purified it was drained into large drums and 
stored in a hot room at 150 °F.  Next, ammonium (anhydrous ammonia) was 
added to the acid to make a slurry mixture in 50 gallon reactors through 1978, 
after 1978 this was done in a larger reactor (400 gallons).  The slurry was stored 
in 55 gallon drums or 200 gallon totes.  There was potential for exposure during 
the purifying process of production from occasional leaks and spills.  Other 
opportunities for exposure occurred when the workers replaced the filters, when 
the metal plates from the cells were cleaned or replaced, and when quality control 
samples were collected.    
Through the end of 1977 the material was dried by a tray dry method.  
From 1978 until 1981, a variety of drying methods were attempted including a 
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 filter press and oven with a pulverizer method and a Bird Young™ filter/blender-
dryer method.  After 1981 the inert material was evaporated from the acid using a 
spray dryer.  The ammonium salt was blended, packaged, and finally shipped to 
various locations.  During the drying process there was potential for very high 
inhalation exposure while spray-drying and packaging the powder.  In the 1990s, 
a curtain barrier was used in the Spray Dry Room to isolate the ammonium salt 
and reduce contamination.  In 1999 a plexi-glass barrier was installed in the Spray 
Dry Room, and in 2000 the use of full-face respirators was mandated for the 
production workers. 
Work History 
 Work history records indicating the job department, job title, and start and 
end dates were used to identify the duration and calendar period of employment.  
Several thousand job titles were standardized to represent the workers’ duties for 
each position.  A total of forty-five unique job titles were identified and used for 
the Chemical Division from 1951-2002.  All job titles for pre and post-production 
Chemical Division workers, and all workers in the Non-Chemical Division, were 
standardized by division and year of employment.     
Exposure Data 
There were a total of 205 personal and 659 area APFO/PFOA (APFO 
C8HF15O2NH3; and PFOA C8HF15O2) air measurements used in the quantitative 
exposure assessment.  Air data collection for APFO/PFOA began in 1977 and 
ended in 2000 (Table 2).  Both PFOA and APFO were sampled depending on the 
process step and exposure (i.e., vapor or particulate phase). The following 
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 sampling media were used to collect PFOA vapors; Impinger (0.01N NaOH 
methanol), silica gel tubes, and ethylene glycol coated Tenax tubes through the 
1980s.  After the 1980s, PFOA was captured using Tenax tubes, silica gel acid 
tubes and finally OVS–XAD-4 resin tubes.  From 1977-1999, APFO was 
collected with tared 0.8 micrometer pore size Nuclepore filters; with a switch to 
OVS-XAD-4 resin tubes in 2000.  The PFOA anion (PFO-) was the measured 
analytic compound using gravimetric gas chromatography, flame ionization and 
electron capture analyses. 
All the personal air samples were breathing zone samples taken during 
various exposure tasks including; charging, draining, fractionation, stabilization, 
changing filters, spray drying, grinding, manual crushing, dumping trays, 
packaging the material, and cleaning.  The area samples were taken in the 
production room and represented the background exposure value during 
production and non-production activities.  Both personal and area samples were 
short term, task-based samples—the duration varied from twenty minutes to over 
two hours, depending on the task.  Using the data from the air measurements and 
professional judgment regarding the amount of time spent at the various exposure 
tasks performed during a typical shift, we estimated daily inhalation exposure 
values. 
Exposure Values: Daily Time-Weighted Averages  
We created an exposure data matrix with annual estimated time weighted 
average (TWA) exposure values for all jobs held from 1947 through 2008. For 
Chemical Division workers during production years (1951-2002), we estimated a 
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 daily TWA in mg/m3 for each year-job title-department combination using the 
task-based arithmetic mean and duration of task per shift.  We calculated close to 
3,000 TWAs from 1951 through 2002 to create the EDMs. Exposures for the 
concurrent year were used when available.  Fewer than 20% of the TWAs were 
computed directly from concurrent year measurements.  There were 2,462 
imputed TWAs using air measurements from a specific job title and department 
combination, but different year(s).  The imputed TWAs in years without sampling 
data were calculated by adjusting for production rates—reflected in the amount of 
time spent conducting an exposure task.  The amount of time for an eight hour 
shift was divided into three parts; 1) time spent outside of the production room 
(“Outside Production Room”), 2) time spent in the production room without 
directly performing a APFO/PFOA-related exposure task (“Inside Production 
Room: No Exposure Task”), and 3) time spent in the production room 
conducting APFO/PFOA-related exposure tasks (“Inside Production Room: 
Exposure Task”). For the time spent “Outside Production Room”, we used a 
constant value of 0.001 mg/m3.  
The daily TWA exposure in mg/m3 of air was calculated as:  
Cj = ∑ni=1 citi/ ∑ni=1 ti      Equation (1) 
  
Cj are the mean concentrations in mg/m3 of PFO- for a given job title for 
the ith worker, ti are the amounts of time in minutes and ci are the air 
concentrations for each of n distinct work-time areas.  A total of 480 minutes 
were used in the denominator for each calculation representing an eight-hour 
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 work shift. The method for estimating the TWA that incorporates different task-
based exposures for the same job are displayed in Tables 3 and 4. 
All Non-Chemical Division workers’ daily TWAs were estimated using an 
APFO/PFOA background exposure estimate—taken from facility area and public 
environmental sampling data.  Likewise, Chemical Division workers’ pre and 
post-production (1947-1951, and 2003-2008) daily TWAs were calculated with a 
similar method as all Non-Chemical workers.  Specifically, prior to the start of 
production, we used a step-wise algorithm to estimate TWAs.  Area samples from 
non-production measurements and from local and regional environmental air data 
provided by the Minnesota Pollution Control Agency (MPCA) and reported by 
Stock et al. (2004) were reviewed.   Stock et al (2004) measured atmospheric 
fluorinated telomer alcohols (FTOHs), which degrade in the environment to 
PFOA, at several locations in North America with a range of concentrations of 
1.65 x 10-7 to 1.1 x 10-8 mg/m3.  We calculated a daily TWA for all Chemical 
Division workers by increasing exposure by 50% for each year from 1947-1951 
starting with a baseline TWA established with expert input and the review of the 
aforementioned non-production area measurements and atmospheric data.  We 
assumed the annual increase would be based on a gradual production rate 
increase, which would reflect background exposure levels.  Workers in the Non-
Chemical Division were assigned the same initial ambient measurements that 
were assigned to Chemical Division workers in 1947.  These increased by 50% 
every three years through 1951.  From 1952 through 1959 the daily TWA 
increased by one order of magnitude to account for transient exposures.  For the 
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 1960s we increased the TWA by one order of magnitude.  The following decades 
through 2002, we increased exposure once more to reach 1.0 x 10-5 mg/m3 to 
account for the change in production rates. 
After production ceased in 2002, we continued to assign exposure levels 
(daily TWAs) for all workers based on their division from the on-site chemical 
residuals.  We decreased the Chemical Division workers’ TWAs by 50% annually 
through 2008. The calculation for the Non-Chemical Division workers’ TWAs 
followed the same method; however the TWAs were one order of magnitude 
lower than the Chemical Division workers (Table 6). 
Exposure Models: Annual Exposure Estimates 
Using the APFO/PFOA values from the EDMs linked to the workers’ job 
history files we built two exposure models to estimate annual dose from the 
TWAs: 1) a standard cumulative exposure model: potential cumulative dose 
(PCD) and, 2) a clearance weighted exposure model: cumulative clearance 
weighted dose (CCWD) that accounts for the retention and elimination of PFOA 
from the body.  The first model is a cumulative estimate of the inhaled exposure 
over time based on the sum of the daily TWAs from the individual’s work history.  
The second model is a first order kinetics model based on the estimated human 
half-life of serum-PFOA used to predict clearance of PFOA from the body. While 
not a complete physiologically based pharmacokinetic model, the CCWD model 
provides an estimate of body burden in periods where exposure is decreased or 
eliminated.  Methods similar to the exposure modeling for the CCWD model have 
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 been previously described to capture an estimate of time-varying body burden 
compared to a standard cumulative exposure model (Checkoway, 1990).   
To estimate total annual dose we converted the daily TWA in mg/m3 
(Equation 1) to milligrams (mg) of exposure by multiplying the TWA with a 
standardized breathing rate taken from the United States Environmental 
Protection Agency (US EPA) Exposure Factor Handbook (1997) for an average 
adult conducting light work—using 1.0 cubic meter (m3) of air inhaled and 
exhaled per hour for an eight hour work shift.   The sum of the total number of 
days an employee worked per year and the daily dose in mg gives a dose rate 
using the following equation: 
Ej = Cj (mg/m3)(1.0 m3/1 hour)(8 hours/1 day)(# work days/year)    Equation (2)  
The Ej represents the amount of APFO/PFOA (the exposure) entering the body in 
milligrams for each year worked, j, and Cj is the daily TWA in mg/m3 taken 
directly from the EDM and linked to the worker’s HR profile. 
We calculated each worker’s annual cumulative dose and clearance 
weighted dose profiles using the following equations:  
Potential Cumulative Dose (PCD) estimate of body burden in mg:      
     Equation (3) 
 
Cumulative Clearance Weighted Dose (CCWD) estimate of body burden 
in mg:  
     Equation (4) 
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 In Equations 3 and 4, the Eij represents the estimated dose in mg, j refers 
to the specific year of exposure, n is number of years worked, and i is the ith 
worker.  In the Equation 4, k is the elimination constant, and is equal to ln 2/T1/2.  
T1/2 is the half-life of serum-PFOA in humans, estimated to be between 2.3 and 
3.8 years (Bartell et al., 2009, Brede et al., 2010, Olsen G.W. et al., 2007).   We 
have chosen to use 3.5 years in the half-life model based on data from retired 
workers at the 3M production workers reported by Olsen G.W. et al. (2007).  This 
model accounts for body burden following cessation of or reduction in exposure. 
After exposure ceases body burden will exponentially decline asymptotically.   
Data Analysis 
To analyze the workers’ exposure profiles and compare the two annual 
dose estimates, we began by reviewing the distribution of cumulative dose 
estimates for all workers.  We evaluated the range of data from the cumulative 
estimates to guide in the demarcation of the dose ranges and establish the 
exposure groups.  We reviewed the workers’ exposure profiles comparing 
estimates from the two models at specific ages for the total population.  The four 
ages evaluated were each decade, age 30 through 60.  This allowed us to explore 
differences in exposure levels between the PCD and CCWD model and determine 
which ages and exposure groups were most sensitive to exposure 
misclassification.  We displayed three groups of chemical production workers 
representing a range of job titles in the main production APFO building.   
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 RESULTS 
Study Population 
 Workers averaged 15 years of employment with a maximum of 59 years.  
The average age at first and last employment was 30 and 43 years, respectively.  
Males represented more than three-quarters of the population with 3,716 males 
and 952 females.  The data in Table 5 show workers’ range of cumulative 
exposures for both models.  The groups were split by workers who; ever worked 
in the Chemical Division, those who only worked in the Non-Chemical Division, 
and all workers.  More males were represented in the Chemical Division, and on 
average they started younger and completed work later in life, compared to the 
Non-Chemical Division.  Close to two-thirds (63%) of those who ever worked in 
the Chemical Division also held jobs in the Non-Chemical Division, often making 
the shift from a Chemical to Non-Chemical job with increasing age.   
Exposure Analysis 
 The Chemical Division’s range of daily TWAs was 1 x10-8 to 3.79 x 10-1 
mg/m3, and the Non-Chemical Division’s range of TWAs was 1 x10-8 to 1 x10-5 
mg/m3.  Table 6 shows the range of TWAs for both divisions by year.  It also 
includes job titles with specific APFO-exposure tasks within the Chemical 
Division.  The data were log normally distributed.  We used the range of the 
potential cumulative dose estimates to create six exposure groups representing 
orders of magnitude differences with a range starting from less than 0.001 mg up 
to greater than 10 mg (Table 7).  The majority of all workers were located in the 
mid-range groups (groups 3-5; >0.01- 10 mg of APFO/PFOA).  The highest 
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 exposure group (group 6; >10.0 mg of APFO/PFOA) contained few workers 
overall, and almost none were from the Non-Chemical Division. 
The majority of workers’ exposure group classifications changed with age. 
We evaluated the cumulative exposure for all workers at 30, 40, 50, and 60 years 
of age comparing estimates from the two models.  The mean and median 
estimates of potential cumulative dose and cumulative clearance weighted dose in 
mg of APFO/PFOA for the workers by age are provided in Table 8.  The age 
groups with the greatest potential for exposure misclassification were the final 
two decades evaluated. The trend for median values increases with age for both 
model estimates.  However the highest mean exposure values occur at age 40 and 
age 50 for the PCD and CCWD models, respectively.  When evaluating the whole 
population, the correlation between the estimates from the two models illustrates a 
greater gap between dose estimates with increasing age.  Figure 1 displays the 
distribution of estimates on a log scale between the two models and the 
correlation co-efficient for all four of the selected ages.   
Worker Exposure Profiles 
We displayed the exposure profiles for three sets of workers with the same 
job title for part of their career.  These data represent the comparison between the 
cumulative annual estimates using the PCD model and the annual exposure 
estimates from the CCWD model.  Figures 2, 3, and 4 show a range of exposures 
for APFO production workers, starting with relatively low to very high-level 
exposed personnel.  Figure 2 shows relatively low-dose estimates for production 
workers where worker 1 is in group 3 at age 30 for both model estimates, however 
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 by age 40 s/he decreases to group 2 only for the CCWD model annual estimate.  
Worker 2 starts in the low group and by age 60 is part of exposure group 4 based 
on the PCD model estimate, compared to group 2 for the CCWD estimate.  
In Figure 3, we display two workers with mid-level overall dose estimates 
for APFO production workers.  At age 50, worker 1 is part of the highest 
exposure group (group 6) and a middle exposure group (group 3), for the PCD 
and CCWD model estimates respectively. Therefore, when using the values from 
the standard cumulative model this worker reaches a high exposure group early on 
and stays there—but by incorporating the serum elimination half-life, this same 
worker changes to lower rankings with time.  Finally, figure 4 shows two workers 
with the same job titles, who held high-level exposure jobs compared to the 
aforementioned workers.  Both workers show a distinct separation between the 
exposure group rankings by age 50, moving to a lower exposure group when 
using the CCWD estimates compared to the PCD estimates.  
DISCUSSION 
 
In this study we evaluated the APFO/PFOA exposure profiles of 4,668 
workers at the Cottage Grove, MN 3M plant comparing dose estimates from two 
cumulative time-dependent exposure models.  Each worker had a unique exposure 
profile based on the combination of their job title(s), work department(s), and 
year(s) of employment.  Job assignments changed over time—as did each 
worker’s exposure. We expected a divergence in the two annual exposure 
estimates by worker due to the nature of the models; however, what was not 
apparent was the amount of potential misclassification depending on the age and 
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 intensity of exposure.  On average, the workers most vulnerable to potential 
misclassification were those individuals with estimates in the mid to high 
exposure groups and workers with increasing age.  This may have ramifications 
for health-outcome analyses.  Using the standard cumulative model negates any 
elimination that occurs and may inflate the exposure estimates with time.  By 
contrast, the clearance-weighted model more closely reflects time varying body 
burden—especially after exposure has ceased.  
Many workers who were part of the Chemical Division started at an early 
age, had high exposures early on, and switched to jobs with lower exposures later 
in their career.  In this population, workers had their greatest exposure potential in 
the earliest two decades of their work-life, compared to the later years.  When this 
is true, many workers with long tenure—and early age high-level exposure—
often ended their career with a low body burden and a relatively low exposure 
group ranking when using the annual estimates from the clearance-weighted 
model instead of the traditional cumulative model. With increasing age, many 
workers show a greater difference between the CCWD and PCD estimates—
making the choice of model more important with age. 
When interpreting the results of our exposure group rankings and the 
models chosen, some study limitations are clear.  We made several assumptions 
related to our daily TWA calculations.  The majority of our air monitoring 
samples came from the final years of production.  We assumed that these 
represented earlier years’ exposures with the adjustment of production rates.  We 
used a percentage of the mean concentration based on the relative production rates 
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 by year.  Additionally, sample collection methods and analysis methods of 
APFO/PFOA changed over time with increasing sensitivity to detect lower level 
airborne concentrations in the later years of production.  With the data from 
earlier years, we may not have captured very low airborne concentrations of 
APFO/PFOA, which may lead to an underestimate of exposure.  
Another study limitation of note is the use of the CCWD model as a 
surrogate measure of body burden.  We did not have a complete pharmacokinetic 
model that considers all routes of exposure (inhalation, dermal, oral) and several 
other biological parameters.  However, we calculated the internal dose based on 
the main exposure route, i.e. inhalation, a novel approach. We did not evaluate 
other routes of exposure such as dermal absorption and/or oral exposure; 
however, our assumption is that the majority of workers’ exposure is through 
inhalation compared to other routes of exposure and that the other routes of 
exposure would be equally negligible for all workers.    
PFOA is on the priority list to be evaluated for carcinogenicity by the 
International Agency for Research on Cancer (IARC) of the World Health 
Organization (WHO).  A formal review of the literature conducted by the US 
EPA’s Science Advisory Board (SAB) suggested that PFOA is “likely to be 
carcinogenic to humans” (US EPA, 2006).  The validity of any health outcome 
study that presupposes an association between a specific level of exposure and 
occurrence of disease is contingent on utilizing exposure models that best 
represent an individual’s true body burden.  
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 Various occupational studies have attempted to evaluate real time 
exposures.  In a study on lung cancer, researchers found that workers with two 
unique time varying exposure profiles, yet the same cumulative exposure, resulted 
in different lung cancer rates when compared to controls (Hauptmann et al., 
2002).  Other researchers have attempted to eliminate exposure misclassification 
and more accurately represent exposure by using half-life and other time-
dependent exposure models.   An exposure reconstruction conducted by Gallagher 
et al. (2011) from a case-control study on perchloroethylene (PCE)-contaminated 
drinking water and the risk of breast cancer found that misclassification might 
have occurred in a prior analysis mainly among subjects with low exposure levels.  
The initial exposure assessment used a proxy measure of PCE while in the 
updated assessment the investigators utilized more precise estimates of time-
dependent exposure.  The results of this study indicated that with a more accurate 
estimate of exposure, women in the highest exposure group had a greater risk of 
breast cancer.  In another occupational exposure study investigators showed that 
exposure to pesticides in apple thinners when using a time-integrated exposure 
model, compared to a traditional model, was more predictive of dose when 
compared to biological samples.  The model incorporated exposure over time 
instead of assuming a fixed exposure independent of time (Doran et al., 2003). 
Occupational studies that have estimated APFO/PFOA exposures have 
relied on work history profiles and serum-PFOA data.  Kreckman et al. (2009) 
completed an exposure reconstruction with workers using the distribution of 
serum concentrations to determine exposure intensity with concurrent job titles 
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 that were recorded at the time of blood draw.  They found high variability in the 
blood levels of workers with the same job titles.  This may be, in part, due to the 
long half-life of serum-PFOA and the possibility of frequent job changes or the 
occasional high-exposure event.  Ubel et al. (1980), in his paper of the health 
status of fluorochemical workers at 3M, reported blood levels of total organic 
fluorine to be elevated related to intensity of exposure and duration of 
employment.  This shows that the precision of individual-level dose estimates can 
be enhanced when using the workers’ full employee history, including the time 
spent working in each job title and the related exposure estimates.  We attempted 
to include these variables in our exposure assessment.         
Our aim was to demonstrate methods for reconstructing the daily exposure 
of this cohort by building an exposure data matrix with daily TWAs for each job 
title, department and year of exposure combination.  Additionally, the purpose of 
this paper was to provide individual-level annual dose estimates of APFO/PFOA 
that closely represent time-dependent body burden.  These data capture a wide 
range of cumulative estimates, which will help inform the scientific community 
regarding what level of APFO/PFOA exposure affects disease outcomes.  The 
exposure estimates from both models provide alternatives for study investigators 
to examine specific assumptions about time related exposures, chemical retention 
and elimination, and disease onset.  In our cohort, the choice of exposure model 
becomes critical with increasing exposure estimates and age, and in particular 
when evaluating the risk of long-latency disease outcomes.  We have 
hypothesized that the annual dose estimates from the CCWD model capture 
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 variability of body burden over time accounting for retention and elimination of 
APFO.  These annual estimates, along with cumulative estimates of the CCWD 
model, provide an alternative way to characterize exposure.  However, 
confirmation of this assumption can only be made through the examination of 
biological data correlated to dose estimates.  Overall, these data allow for a future 
exploration of risk of disease related to dose during potential etiologic ages.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
 REFERENCES 
Bartell SM, Calafat AM, Lyu C, Kato K, Ryan PB, Steenland K. 2009. Rate of 
decline in serum PFOA concentrations after granular activated carbon 
filtration at two public water systems in Ohio and West Virginia.  Env. 
Health Perspect 118(2): 222-228. 
Biegel, L. B., Hurtt, M. E., Frame, S. R., O'Connor, J. C., & Cook, J. C. 2001. 
Mechanisms of extrahepatic tumor induction by peroxisome proliferators 
in male CD rats. Toxicological Sciences 60(1):44-55.  
Brede E, Wilhelm M, Göen T, Müller J, Rauchfuss K, Kraft M, et al. 2010. Two-
year follow-up biomonitoring pilot study of residents’ and controls’ PFC 
plasma levels after PFOA reduction in public water system in Arnsberg, 
Germany. Int J Hyg Environ Health 213:217–223. 
Checkoway H., Pearce N., Hickey J.S., Dement J.M. 1990  Latency analysis in 
occupational epidemiology.  Archives of Environmental Health, 45(2); 95-
100. 
Davis M., Hart J., Laden F., Garshick E., Smith T. (2011) A retrospective 
assessment of occupational exposure to elemental carbon in the U.S. 
trucking industry.  Env. Health Per. 119(7), 997-1002. 
Doran E., Fenske R., Kissel J., Curl C., Simcox N. (2003).  Impact of Dermal 
Absorption in Occupational Exposure Assessment:  Comparison of Two 
Models for Agricultural Reentry Workers Exposed to Azinphosmethyl.  
Appl Occu & Env. Hy 18(9), 669-677. 
Gallagher L., Vieira V., Ozonoff D., Webster T., Aschengrau A (2011)  Risk of 
breast cancer following exposure to tetrachlroroethylene-contaminated 
drinking water in Cape Cod, Massachusetts: a reanalysis of a case-control 
study using a modified exposure method.  Env. Health 10(1), 47-63. 
Gilliland, F. D., & Mandel, J. S. 1993. Mortality among employees of a 
perfluorooctanoic acid production plant. Journal of Occupational 
Medicine, 35(9), 950-954.  
Hauptmann, M., Pohlabeln, H., Lubin, J. H., Jöckel, K.-H., Ahrens, W., Brüske-
Hohlfeld, I. and Wichmann, H.-E. (2002), The exposure-time-response 
relationship between occupational asbestos exposure and lung cancer in 
two German case-control studies. American Journal of Industrial 
Medicine, 41: 89–97.  
73 
 
 Kreckmann KH, Sakr CJ, Leonard RC, Dawson DJ 2009. Estimation and 
Validation of Biomarker-Based Exposures for Historical Ammonium 
Perfluoroocanoate. J of Occ and Env Hygiene (6),511-516. 
 
Lundin J, Alexander B, Olsen G, Church T. 2009. Ammonium perfluorooctanoate 
production and occupational mortality. Epidemiology 20(6):921–928. 
 
Neiuwenhuijsen M, Paustenbach DR and Duarte-Davidson R.2006. New 
developments in exposure assessment: the impact on the practice of health 
risk assessment and epidemiological studies.  Environ Int 32.996-1009. 
 
Olsen GW, Burris JM, Ehresman DJ, Froelich JW, Seacat AM, Butenhoff JL, 
Zobel LR.2007. Half-life of serum elimination of perfluoroocatnesulonate, 
perfluorohaxanesulfonate, and perfluoroocatnaoate in retired 
fluorochemical production workers.  Env. Health Perspect 115: 1298-
1305. 
 
Slavan A, Thomaseth K, Bortot P, and Sartori N 2001 Use of a toxicokinetic 
model in the analysis of cancer mortality in relation to the estimated 
absorbed dose (2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-TCDD).  The 
Science of the Total Env.(274), pp. 21-35. 
 
Stock L., Ellis D., Martin J., Muir D., Polyfluorinated Telomer Alcohols and 
Sulfonamides in the North America Troposphere.  Environ. Sci. Technol.  
2004, 38, 991-996. 
 
US EPA Exposure Factor Handbook.  August 1997.  Final Report, pg.22. 
US EPA SAB Review of EPA’s Draft Risk Assessment of Potential Human 
Health Effects Associated with PFOA and Its Salt.  Report 2006. 
Ubel F., Sorenson S., Roach D. (1980). Health status of plant workers exposed to 
fluorochemicals: preliminary report. American Industrail Hygiene 
Association. (41) 584-589. 
Williams PR and Paustenbach DJ. 2003.Reconstruction of benzene exposure for 
the Pilofilm cohort (1936-1976) using Monte Carlo Techniques. Journal 
Toxicol Environ Health 66  677-781. 
 
Yao X. and Zhong L. (2005).  Genotoxi risk and oxidative DNA damage in 
HepG2 cells exposed perfluorooctanoic acid.  Mutat Res. 587 (1-2):38-44.
74 
 
Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.                            Cottage Grove: APFO/PFOA Production by Year 
Year Pounds 
 
Year 
 
Pounds 
 
1951-1959 200-500 1976 31,200 
1960-1969 900-1,200 1977 56,400 
1970-1971 1,200-2,000 1978 60,000 
1972 18,000 1979 36,000 
1973-1974 36,000* 
 
1980-1989 
 
2,000* 
1975 20,400 
 
1990-1999 
 
360,000* 
*Values are an average annual value 
 
Table 2. Air Sampling Data: Analytic Method Measuring the Carboxylate Anion (PFO-) 
    
Years Personal Samples Area Samples Total Samples 
1977-1980* 67 95 162 
1981-1990* 45 101 146 
1991-1999* 19 42 61 
2000 APFO 23 214 237 
2000 PFOA 27 143 170 
2000 Both* 24 64 88 
2000 Total 205 659 864 
*Approximately half PFOA (vapor) and half APFO (particulate) samples 
75 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.   Cottage Grove:  Time Weighted Average (TWA) Exposure Calculation: 1990  
1990: 8-Hour Tasks: Chemical Department 
 Operator- Kettle Room  APFO Number of Samples Average mg/m3 480 min/day 
Outside Production Room 
Professional 
Judgment* 0.001 434** 
 
Inside Production Room: No Exposure Task  
 101 0.012 32** 
 
Inside Production Room: Exposure Task 
 12 0.051 14** 
*Professional Judgment is a best estimate of exposure without PFO- measurements from experienced industrial hygiene 
staff. 
**These minutes were estimated based on exposure task sampling time, expert input, and production records. 
 
 
0.003 mg/m3 
 
 
Table 4.   Cottage Grove:  Time Weighted Average (TWA) Exposure Calculation: 2000  
2000: 8-Hour Tasks: Chemical Department 
 Operator- Kettle Room  APFO Number of Samples Average mg/m3 480 min/day 
Outside Production Room 
Professional 
Judgment* 0.001 434** 
 
Inside Production Room: No Exposure Task  
 101 0.012 2** 
 
Inside Production Room: Exposure Task 
 12 0.051 44** 
*Professional Judgment is a best estimate of exposure without PFO- measurements from experienced industrial hygiene 
staff. 
**These minutes were estimated based on exposure task sampling time, expert input, and production records. 
 
 
0.006mg/m3 
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Table 5. Cottage Grove Workers:  1947-2008 (N=4,668) 
 Chemical Division (ever) Non-Chemical Division (only) All Workers 
Number of Workers 2,366 2,302 4,668 
    
Number of Males (%), Females (%) 2,059 (87%), 307 (13%)  1,657 (72%), 645 (28%)  3,716 (80%), 952 (20%)  
Average age at first employment 29, (16-64) 30, (17-73) 30, (16-73) 
    
Average age at last employment 46, (19-92) 41, (19-85) 43, (19-92) 
    
Average number of years worked 17, (1-59) 10, (1-47) 15, (1-59) 
    
Range mg APFO/PFOA (PCD model) 1.36 x 10-5  - 2.12 x 10+3 3.66 x 10-5  - 2.37 x 10+1 3.66 x 10-5  - 2.12 x 10+3 
    
Range mg APFO/PFOA (CCWD model) 1.02 x 10-5  - 5.12 x 10+3 1.36 x 10-5  - 8.29 x 10+1 1.02 x 10-5  - 5.12 x 10+3 
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 Table 6. Daily Time Weighted Average (TWA) Range: APFO Exposure 
   
Job Title Years Range of daily TWAs (mg/m3) 
All Jobs Non-Chemical Division 1947-1952 1x10-8  - 1x10-7 
All Jobs Non-Chemical Division 1953-2002 1x10-7  - 1x10-5 
All Jobs Non-Chemical Division 2003-2008 1.56 x10-7  - 5x10-6  
   
Non-APFO Jobs Chemical Division 1947-1952 1x10-8  - 1x10-4 
Non-APFO Jobs Chemical Division 2003-2008 1.56 x10-6 - 5 x10-6 
   
Clerk 1956-1961 0.001 
   
Custodian 1959-2002 0.0011-0.002 
   
Finished Goods-Floor Checker 1997-2002 0.002 
   
Foreman 1954-1976 0.0026-0.007 
   
Head Cell Operator 1956-1999 0.0015-0.003 
   
Helper 1956-1978 0.006-0.379 
   
Lab Technician 1956-1966 0.017-0.0023 
   
Manager 2000-2002 0.0003 
   
Operator-Spray Dryer 1978-2002 0.011-0.124 
   
Operator- Kettle Room APFO 1956-2002 0.0017-0.04 
   
Operator-Kettle Room non-APFO 1956-2002 0.001-0.008 
   
Pilot Plant Technician 1954-1962 0.0017-0.0023 
   
Process Engineer 1956-1961 0.0006-0.0011 
   
QC Foreman 1956-1960 0.0001 
   
Senior Pilot Plant Assistant 1956 0.0017 
   
Supervisor 1954-2002 0.0001-0.0003 
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Table 7. Number of Workers by Category: Cumulative Dose Estimate:  APFO/PFOA (mg)  
 
 Chemical Division (ever) Non-Chemical Division (only) All Workers 
 
1 (0-.001) 36 83 119 
2 (>.001-.01) 20 447 467 
3 (>.01- 0.1) 217 793 1010 
4 (>0.1- 1.0) 816 849 1665 
5 (>1.0-10) 904 127 1031 
6 (>10) 373 3 376 
 
Total Number of Workers 2366 2302 4688 
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Table 8. 
Workers' APFO/PFOA Dose Estimates:  Mean and Median Value in mg by Age: 
Potential Cumulative Dose (PCD) and Cumulative Clearance Weighted Dose (CCWD) Models 
Age 
PCD Model CCWD Model 
 
Mean Median 
 
Mean Median 
30 
 
4.8 0.07 23.1 0.15 
40 8.9 0.13 35.3 0.30 
50 8.2 0.18 37.6 0.41 
60 8.3 0.24 31.6                       0.49 
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   Figure 1.  Distribution by Age: Comparing the Potential Cumulative Dose (PCD) and the 
  Cumulative Clearance Weighted Dose (CCWD) Model Estimates in mg APFO/PFOA 
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CHAPTER 5:  OCCUPATIONAL EXPOSURE TO 
PERFLUOROOCTANOIC ACID AND ITS PRIMARY SALT, 
AMMONIUM PERFLUOROOCTANOATE AND RISK OF 
CANCER MORTALITY IN WORKERS 
 
 
 The extent of human health effects from exposure to perfluorooctanoic 
acid (PFOA) and its primary salt, ammonium perfluorooctanoate (APFO) are 
unknown.  In toxicological and occupational studies, exposure to APFO/PFOA 
has been associated with an increased risk of non-malignant tumors and cancer 
mortality, respectively.  These effects were observed in the context of laboratories 
where animals were given high doses of APFO/PFOA, and in occupational 
settings with relatively high-level exposure for workers who produced APFO.  
The purpose of this paper was to evaluate the risk of cancer mortality in a cohort 
of 3M workers with various levels of APFO/PFOA exposure.  To accomplish this, 
we utilized a newly created exposure data matrix (EDM).  The EDM was 
constructed using air measurements for specific jobs—in place of previous 
analyses that evaluated a worker’s job title or location as the exposure measure. 
This was a retrospective occupational mortality study with 9,027 workers from 
two 3M plants in Minnesota, evaluating the risk of a cancer death associated with 
an individual’s exposure over time. We examined workers’ risk of cancer 
mortality for six a priori cancers—bladder, breast, kidney, liver, pancreatic, and 
prostate cancers using extended Cox proportional hazard models and standardized 
mortality ratios (SMRs) were calculated from Minnesota population death rates.  
Hazard Ratios (HRs) for the internal evaluation were calculated using the 
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 workers’ continuous exposure estimates, exposure group rankings, and exposure 
during time-windows—all as potential risk factors for cancer mortality.  To 
account for the effect of cancer latency, we lagged the models by ten years.  
Models were stratified by gender, and adjusted for the workers’ first year of 
employment.   
 There were a total of 2,979 identifiable deaths in our cohort, and of these 
there were 72 prostate cancer deaths, 48 pancreatic cancer deaths, 16 bladder 
cancer deaths, 25 (female) breast cancer deaths, 24 kidney cancer deaths, and 15 
liver cancer deaths.  The SMRs for Cottage Grove showed no excess of cancer 
deaths.  Within Cottage Grove, workers who were ever involved in chemical 
production of APFO observed 16 prostate cancer deaths compared to 13 expected.  
The internal exposure group evaluations showed two of the six cancers examined 
have a potential dose-response relationship.  There was an elevated, but imprecise 
risk of dying from prostate cancer for the highest two exposure groups compared 
to the workers in St. Paul [HR=1.22, (95% CI: 0.57, 2.61) and HR=1.27, (95% 
CI: 0.30, 5.28)].  The risk of a pancreatic cancer death was elevated for the second 
highest exposure group—there were no pancreatic cancer deaths in the top 
exposure group.  All other cancers evaluated were at or near no effect level when 
evaluating time-dependent exposure data and specific time-windows of exposure.  
All internal estimates were unstable.  There was limited evidence of consistent 
outcomes to confirm previous study results.  Future mortality and morbidity 
studies based on the EDM may be warranted. 
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 INTRODUCTION 
 
Perfluoroctanoic acid (PFOA) is an eight chain fully fluorinated 
carboxylic acid.  The salts of PFOA have been used as surfactants and processing 
aids for several decades.  As a synthetic chemical surfactant it has a broad range 
of commercial and industrial applications including the manufacture of 
electronics, flame-retardants, non-stick cookware and waterproof textiles 
(Kennedy et al., 2004).  It bio-accumulates and does not break down easily in the 
environment due to the carbon-fluorine bonds.  Although PFOA is not naturally 
occurring, it has been detected in many animal species and environmental 
matrices around the world (Houde et al, 2006).  In the body, it binds to blood 
proteins and is found primarily in blood-serum, liver and kidneys.  PFOA has a 
long serum half-life in humans and there is evidence that its excretion is biphasic, 
where early excretion is more rapid than later excretion (Steenland et al., 2011).  
The production and use of APFO has been phased out over the last decade due to 
concerns about effects on human and environmental health.  
PFOA’s primary salt, ammonium perfluorooctanoate (APFO), was 
manufactured for more than fifty years at the 3M Cottage Grove facility in 
Minnesota.  Workers were predominately exposed to APFO particulate and PFOA 
vapors through inhalation, followed by dermal contact and cross-contaminated 
oral routes of exposure.  Production workers at the Cottage Grove plant had 
potential for significant exposure to APFO and PFOA compared to other non-
production workers and the general public.  The median blood serum-PFOA 
concentration for Cottage Grove APFO production workers ranged from 100 to 
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 5,000 parts per billion (ppb) (Olsen et al., 2003).  In 1999-2000 the National 
Health and Nutrition Examination Survey (NHANES) data on the U.S. population 
reported a geometric mean serum-PFOA concentration of 5 ppb that declined by 
25% to 3.9 ppb in the years 2003-2004 (Calafat et al., 2007).  The most recent 
Fourth National Exposure Report from March 2013 showed the serum-PFOA 
geometric mean concentration for the U.S. population is 5.21 ppb—an increase 
from the former survey (CDC, 2013).  The three–fold difference in the 
concentrations of measured serum-PFOA levels between production workers and 
the general U.S. population emphasizes the magnitude of occupational exposure 
and raises concern regarding its long-term health impact.     
Several animal studies have evaluated the toxicological impact of APFO 
and PFOA.  The health outcomes are broad and include an array of health effects.  
These include an altered immune response, changes in lipid metabolism, low birth 
weight, developmental toxicity and an increase in tumor incidence in some animal 
species.  Data from rodent studies show an increase in the incidence of a triad of 
tumors-pancreatic, liver and testicular cancers (Lau et al., 2007; Loveless et al., 
2008; and Kennedy et al., 2004).  APFO and PFOA are rapidly and completely 
absorbed following inhalation and oral exposure—and to a lesser extent after 
dermal exposure.  There is no evidence that PFOA is metabolized in mammals 
(Kuslikis et al., 1992 and Vanden Heuvel et al., 1991).  PFOA is a known 
hepatocarcinogen in rodents; however, it is not established whether it is 
carcinogenic in humans.  In rats, PFOA acts as an agonist for the peroxisome 
proliferator activated alpha-receptor (PPARα) signaling pathway, which initiates 
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 a sequence of biochemical events known to promote carcinogenesis (Biegel et al., 
2001).  PFOA’s PPARα mode of action and toxicity in rodents has been 
established; however, its toxicological applicability to humans is still uncertain.  
Yao and Zhong (2005) evaluated human hepatoma cells and concluded that 
PFOA exerts a genotoxic effect on the HepG2 cells most likely by way of 
oxidative DNA damage.  In a more recent study, Tilton et al. (2008) examined 
gene expression of an in-vivo trout cancer model to evaluate the potential of 
PFOA’s role as a carcinogen in the absence of peroxisome proliferation.  Tilton 
found that PFOA was a cancer promoter of the liver in the fish.  Like humans, fish 
lack the PPARα mode of action—thus emphasizing the potential health impact of 
PFOA exposure and relevance in humans.   
PFOA is on the priority list to be evaluated for human carcinogenicity by 
the International Agency for Research on Cancer (IARC) of the World Health 
Organization (WHO).  A formal review of the literature conducted by the US 
Environmental Protection Agency’s (EPA) Science Advisory Board (SAB) 
suggested that PFOA is “likely to be carcinogenic to humans” (US EPA, 2006). 
There are limited data on human exposure to PFOA and the possible link to 
cancer.  A recent study of Inuit women in Greenland evaluated PFOA exposure 
from cases and controls with findings of elevated breast cancer cases associated 
with serum-PFOA levels (Bonefeld-Jorgeson et al., 2011).  To date, two 
occupational cohorts have been studied for risk of cancer mortality based on 
human exposure to APFO and PFOA.  A polymer production plant in West 
Virginia was evaluated for various health outcomes.  Leonard et al. (2008) found 
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 some evidence of an excess of kidney, liver, and bladder cancers among workers 
at the DuPont polymer production facility, however there were too few cases to 
draw clear conclusions. An updated analysis of that cohort reported an excess risk 
of malignant and non-malignant renal disease in higher exposed workers 
(Steenland and Woskie, 2012). It is important to note that these workers are also 
exposed to tetrafluoroethylene, a known kidney carcinogen.   The second 
occupational cohort evaluated is the 3M Cottage Grove APFO production plant.  
Two mortality studies with this cohort showed a positive association between 
increasing exposure to APFO and the risk of a prostate cancer death (Gilliland 
and Mandel, 1993; Lundin et al., 2009).  A recent study that examined 
proportional morbidity in a non-occupationally exposed cohort of a community 
residing next to the DuPont plant in West Virginia found a positive association 
between serum-PFOA and kidney cancer for high and very high exposure groups 
(Vieira et al., 2013).   
The goal of this research was to use a newly created inhalation exposure 
data matrix and evaluate 3M workers’ cumulative exposure and the workers’ 
mortality experience.  The exposure values for this study include the duration and 
intensity of exposure over time and were taken from air measurements collected 
at the Cottage Grove plant.  This work explores risk by using estimates from two 
exposure models that provide options regarding body burden measurements.  
Specifically, we present an analysis of the risk of death for six a priori cancer 
classifications including bladder, breast, kidney, liver, pancreatic and prostate 
cancers.  These cancers and other health outcomes—such as diabetes and 
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 ischemic heart disease (IHD)—have been highlighted as health outcomes 
associated with exposure to APFO and PFOA and were selected based on the 
aforementioned positive findings in toxicological data and epidemiological health 
studies. 
 
METHODS 
Study Population 
 3M Workers from both Cottage Grove and St. Paul Minnesota plant 
locations were part of this study.  The Cottage Grove campus has operated in 
more than 30 buildings including production and pilot plants. The facility has 
developed numerous products and various goods ranging from Scotchgard to 
Post-it-Notes and has produced specialty chemicals, including APFO, as well as 
products such as films.  The plant was constructed in 1947 and APFO production 
began soon thereafter. APFO production increased substantially over time but was 
phased out completely by the end of 2002. The Cottage Grove population 
consisted of 4,668 members, including 3,993 workers enumerated for the previous 
study and another 675 who were hired between 1997 and 2002 when APFO 
production stopped. The St. Paul worker cohort had been previously enumerated 
by the University of Minnesota and included 4,359 workers. The total cohort 
population of both locations included 9,027 workers.  At the St. Paul location 
workers manufactured tape, abrasives and adhesive products but never were 
involved with APFO production.  Production at the St. Paul facility was gradually 
phased out between 1998 and 2005. There was a small group of 200 workers who 
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 had employment records in both locations.  We included all workers who accrued 
a one-year minimum cumulative employment through 2008 for the Cottage Grove 
population and 1998 for St. Paul.  The cohort members were followed starting 
January 1st, 1947 or their first date of employment, until either their date of death 
or the end of follow-up, December 31st, 2008.  Human resource records were 
abstracted for work history information; job title(s), job department(s), start and 
stop dates for each position a worker held, and personal identifying data.  A job 
exposure data matrix (EDM) was created to estimate exposure across the life of 
the Cottage Grove plant for all chemical workers.  The non-production Chemical 
Division workers, Non-Chemical Division and St. Paul workers were assigned 
estimated exposures from ambient air measurements and professional input.    
Determination of Vital Status 
 We conducted a vital status assessment on all cohort members not 
determined to be deceased in the previous follow-up.   Vital status was first 
determined using the Social Security Administration’s (SSA) data records. A 
commercial skip-tracing vendor was used to confirm the vital status of workers 
who were not clearly identified as alive or deceased through the SSA. We used 
the National Death Index (NDI) to obtain the date of death, state of death, and 
underlying and contributing cause of death for all workers through 2008. The 
causes of death were coded to the International Classification of Disease (ICD) 
version in effect at the time of death.  
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 Exposure Assessment and Exposure Models 
Using work history records we characterized APFO/PFOA exposure as an 
estimate of internal dose based on the inhalation route of entry for all 3M 
workers.  We utilized two cumulative exposure models—one is a standard model 
and the other incorporates the serum-half-life of PFOA to ascertain extended 
burden of this persistent chemical.   
A complete description of the methods to create the worker’s time-
dependent exposure profiles can be found elsewhere (Chapter Four: Occupational 
Exposure to Perfluorooctanoic Acid and its Primary Salt, Ammonium 
Perfluorooctanoate: An Inhalation Exposure Reconstruction Evaluating Two 
Time Dependent Models).  However, a brief summary of the exposure 
reconstruction methods is presented below. 
We calculated a daily time-weighted average (TWA) in milligrams per 
cubic meter of air (mg/m3) using occupational air measurements of both APFO 
and PFOA.  For jobs in the APFO production area of the Chemical Division we 
incorporated the amount of time spent during an eight hour shift in up to three 
pre-defined work-task areas; 1) time conducting exposure tasks in the production 
room, 2) time conducting non-exposure tasks in the production room, and 3) time 
outside of the production room.  A TWA was calculated for each combination of 
job title, location and year to create an EDM that contained 23 departments and 
45 job titles within the Chemical Division for all production years starting in 1947 
through the end of 2008. Job and department combinations in the non-APFO 
production areas of the Chemical Division and the Non-Chemical Division were 
assigned an estimated TWA based on expert judgment. Cohort members from the 
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 St. Paul Plant were assigned a background level based on estimated exposures in 
the general population. The estimated exposures for each job varied by the 
amount of APFO produced over time.   We linked the department, job and year-
specific TWAs to the employees’ work history records.  We calculated 
cumulative estimates of exposure based on the summation of daily TWAs by 
year.  Annual dose estimates were calculated in milligrams (mg) of APFO/PFOA 
after converting mg/m3 into mg by using the standardized breathing rate of 1.0 
m3/hour for an eight hour work shift, taken from the US EPA Exposure Factor 
Handbook (1997) to represent an average adult conducting light work. 
We used two cumulative exposure models to estimate an annual dose 
estimate for each model.   The first is a standard cumulative model:  “Potential 
Cumulative Dose” or PCD.  It is the sum of the workers’ daily exposure 
estimates in milligrams calculated by linking their work history profile to the 
EDM:  The sum of exposures for the ith worker for all job titles held (j), for each 
year (n).  
 (Equation 1) 
 
 
 
The second model: “Cumulative Clearance Weighted Dose” or CCWD, 
accounts for retention and elimination of the chemical from the body by 
incorporating the estimated serum-half life into the cumulative sum of annual 
exposures: The sum of exposures for the ith worker for all job titles held (j), for 
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 each year (n).  This model accounts for the residual impact from the body burden 
of this persistent chemical. 
(Equation 2)    
    
 We divided the workers into six exposure groups, using the range of 
exposure estimates. 
 Cancer Mortality: Outcome of Interest 
 The following causes of death were selected based on observations from 
animal and occupational studies.  These specific selections were also considered 
identifiable based on the size of our study cohort and the national data from 
cancer-specific death rates provided by the National Cancer Institute (NCI, SEER 
statistics 2003-2007).  Three of the a priori causes of death include: cancers of the 
liver, pancreas, and breast, which were selected based on results from animal 
studies (Butenoff et al., 2004; Biegel at el. 2001). In addition, we chose to 
evaluate the risk of death from prostate, kidney and bladder cancers as a follow-
up to the epidemiological studies that have shown a positive association with 
increasing exposure to PFOA and higher rates of cancer mortality (Vieira et al., 
2013; Leonard et al., 2008; Lundin et al, 2009; Alexander et al, 2003; Steenland 
and Woskie, 2012).   
 The International Classification of Diseases (ICD) 10th revision codes 
were used to classify the underlying cause of death and include: liver cancer, c22-
c24 (formally 155-156 in the ICD 9th revision), pancreatic cancer, c25 (ICD 9th 
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 revision: 157); breast cancer c50 (ICD 9th revision: 174-175); prostate cancer, c61 
(ICD 9th revision: 185); and bladder cancer c67-c68 (ICD 9th revision: 188, 189.3-
189.9); and kidney cancer c64-c66 (ICD 9th revision:  189.0-189.2). 
Data Analyses 
 We initially compared the cohort mortality rates to the state of 
Minnesota’s population mortality rates from the National Center for Health 
Statistics data. Age, sex, race, and calendar period, SMRs and 95% confidence 
intervals (CIs) were computed using the National Institute of Occupational Safety 
and Health’s (NIOSH) software for Life Table Analysis System (NIOSH, 1998). 
Complete referent data were available from 1960 onwards, thus our analysis was 
limited to events occurring after 1960.  We estimated SMRs for each location and 
by Division within the Cottage Grove location. 
We further evaluated associations with APFO exposure and risk of dying 
from specific cancers with an internal analysis.  The risk of a cancer death was 
estimated as a function of APFO/PFOA time-dependent dose estimates by 
calculating hazard ratios (HR) with 95% CIs using extended Cox proportional 
hazards regression models (Breslow and Day, 1987 and Kleinbaum, 1996).  
Exposure was classified in six categories based on order of magnitude differences 
on a log scale (≤10-3 through 10 mg APFO). We modeled the risk of death using 
the cumulative exposure estimates for all workers with both models.  The 
analyses were conducted using the PHREG procedures in SAS 9.2.  The time 
covariate was age—starting with age at date of entry into the cohort until 
censored at time of death or the end of the study.  We adjusted for year of entry 
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 into the cohort and stratified by gender.  To evaluate the potential effects of 
latency the exposure was lagged by 10 years. 
 To explore the possibility of biologically important ages of exposure 
related to the development of disease, we evaluated cancer risk based on 
cumulative exposure estimates calculated during specific ages.  We utilized the 
workers’ exposure estimates calculated during two time-windows—the 4th and 5th 
decades of life.  The estimates during these periods capture the annual exposure 
from each employee’s time-window.  We proposed that the selected age-windows 
may be etiologically relevant periods regarding the sensitivity to disease based on 
biological functions and age-related physiological changes.  Thus, we wanted to 
explore the possibility that dose during distinct ages may have the potential to 
affect the risk of cancer.  
RESULTS 
 
The cohort of 9,027 experienced 2,979 deaths. The cohort members from 
the two plants were similar in age at entry into the cohort, but the St. Paul Plant 
was on average six years older at the end of follow-up (Table 1).  Of the 2,979 
deaths for the entire cohort 72 prostate cancer deaths, 48 pancreatic cancer deaths, 
16 bladder cancer deaths, 25 female breast cancer deaths, 24 kidney cancer 
deaths, and 15 liver cancer deaths were identified.  Almost 33% of the entire 
population was deceased by the end of 2008, and the percentage of those who had 
died was higher in the St. Paul group (42%) compared to the Cottage Grove group 
(25%).  St. Paul workers on average were employed more years, 20, compared to 
the average number of years, 14, for all Cottage Grove employees.  Females 
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 represented only 12% of the St. Paul group compared to 21% of Cottage Grove 
workers. We did not have data on race or ethnicity; however, from personal 
correspondence with current and retired workers the population at both locations 
consisted of workers who were predominately of Caucasian background—which 
is consistent with state and county level data reported by the US Census Bureau 
(US Census Bureau; Quick Fact Sheet, MN). 
All workers were assigned to one of six exposure groups (Table 2).  The 
range of cumulative dose estimates for the entire working cohort was log-
normally distributed—many workers had low-level relative exposure values and 
very few had high-level exposure values. The groupings were formed using orders 
of magnitude from the APFO/PFOA mg estimates. 
The characteristics of the workers from each exposure group vary 
substantially.  The workers classified in the top half of the exposure groups 
(groups 4-6) worked for more years, approximately three times more on average, 
and were predominately male compared to the workers in lower exposure groups 
(groups 2-3).  Additionally, the lowest exposure group had the highest percentage 
of employees who were deceased and the oldest mean age of exit from the cohort.  
Table 3 presents the number of cancers per group.  Of these, the highest two 
exposures groups (>1.0 mg APFO/PFOA) contain few cancer deaths compared to 
the lowest exposure group (<0.001 mg APFO/PFOA), which includes the referent 
group of workers in St. Paul. 
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 External Analysis: Standard Mortality Ratios 
 The overall and all-cause cancer SMRs for the entire cohort were 0.92 
(95% CI: 0.89, 0.96), and 0.96 (95% CI: 0.90, 1.03) respectively, demonstrating 
that the 3M workers as a whole have a lower risk of all deaths compared to the 
Minnesota general population.  In Tables 4 and 5, the SMRs are provided for the 
a-priori cancers and ischemic heart disease (IHD) and diabetes stratified by 
location and division.  As a whole, Cottage Grove workers compared to the 
Minnesota population showed lower rates of all cancers selected.  However, 
workers who ever were employed in the Chemical Division at Cottage Grove had 
an increased risk of prostate cancer deaths [SMR=1.18 and 95% CI (0.67, 1.91)].  
The rate ratio was not statistically significant and based on few cases (16 prostate 
cancer deaths). In the St. Paul, referent group, kidney, breast, pancreatic and 
prostate cancer deaths were elevated. 
Internal Analysis: Hazard Rate Ratios 
 The overall risk estimates for all cancer deaths evaluated were at or below 
no effect level based on the time-dependent cumulative and weighted estimates of 
dose (Table 6).  Tables 7 and 8 show the risk estimates of the selected cancers, 
comparing all exposure groups to the St. Paul workers.  The risk of death from 
prostate cancer increased by 22% and 27% for exposure groups 5 and 6, 
respectively, but the estimates were imprecise and not beyond chance.  Both 
prostate and pancreatic cancer deaths showed a dose-response relationship, 
however the results are imprecise.  Additionally, breast, bladder, and liver cancers 
were elevated comparing groups 3, 4 and 5, relative to the St. Paul workers.  
However, there was no apparent dose-response relationship and only four or 
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 fewer cancer deaths resulted by group (Table 7).  Table 8 data show an increase 
only for bladder and liver cancer deaths combining the top three exposure groups 
compared to the St. Paul workers (six and four cancers respectively).  When 
lagging the two dose estimates by 10 years there were no significant changes in 
the results (Table 9). 
 We evaluated the risk of a cancer death based on the exposure groupings 
for two time-windows (Tables10 and 11).  We found negative associations with 
exposure to APFO/PFOA for many of the selected cancers, during the fourth 
decade of life (age 30-39 years) except there was an increase in pancreatic and 
prostate cancer deaths observed in the low exposure group (using the clearance 
weighted model).  Both bladder and liver had elevated risks for the high exposure 
groups—these results were all imprecise.  During the fifth decade (age 40-49), 
again bladder and liver cancer deaths were elevated for the high exposure groups, 
but based on small numbers (five and six deaths respectively).  The risk of a 
prostate cancer death decreased for both low and high exposure groups in the fifth 
decade of life.  
DISCUSSION 
 
In this cohort we did not observe a clear association between APFO 
exposure and the causes of death of interest. There was no excess in mortality for 
all six specific cancer-related deaths when evaluating the workers’ cumulative 
exposure over time. When examining the time-dependent APFO/PFOA exposure 
groupings we observed a small, but imprecise increase in risk of prostate and 
pancreatic deaths for the highest exposure groups compared to the St. Paul 
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 workers.  This and the SMR of 1.18 (95% CI 0.7, 1.9) for prostate cancer death in 
workers who had ever worked in the Chemical Division is similar to that observed 
in the previous mortality study of the Cottage Grove population.  Bladder cancer 
deaths were elevated for three exposure groups compared to the referent group, 
but the estimates were imprecise and did not exhibit an exposure-response 
relationship.  Death from liver cancer was inconsistent—and higher in the mid-
range exposure group—group three, than in higher exposure groups, four and 
five.  These results were based on fewer than five cancers by exposure group and 
therefore are limited by number.  All other cancers were not associated with 
APFO/PFOA exposure and the results lacked statistical significance.  Diabetes 
mortality was observed as increased in the St. Paul workers overall, and in the 
Chemical Division workers within Cottage Grove.  When lagging the models by 
ten years, we observed a similar, but weaker association for all outcomes in the 
highest exposure groups with the exception of bladder and liver cancers.   
This was the third mortality study using the Cottage Grove cohort to 
evaluate cancer mortality related to APFO/PFOA exposures at work; however the 
defined populations vary by study.  The first study by Gilliland and Mandel 
(1993) required six months of employment for study inclusion—while the follow-
up (Lundin et al, 2009) and the current studies have used a minimum of one year 
of employment.  The current study population has more than a decade of 
additional working years and includes the non-occupationally exposed workers 
from a 3M St. Paul plant.  The purpose of this inclusion was to have a referent 
population that represented the overall Cottage Grove workers in order to 
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 minimize potential confounding.  The St. Paul Plant employees are unionized 
employees working for the same company. This allowed for a more in-depth 
internal evaluation of cancer mortality using a group of 3M workers with a similar 
socio-economic status as the referent population.   
 When interpreting the results of this cancer mortality analysis 
some limitations are apparent and should be considered.  Specifically, there was 
potential for exposure misclassification from the inhalation exposure data matrix. 
Exposure misclassification can depend on many factors (e.g., transient exposures) 
that could affect a worker’s annual exposure estimates.  The CCWD exposure 
model included the half-life value of serum-PFOA to account for retention of the 
chemical in an attempt to represent body burden.  We did not, however, utilize 
blood-serum data to validate the exposure estimates.  The half-life value used 
came from a sub-set of 3M Chemical Division workers—based on a range of half-
life values (2.3-3.8 years), and we chose to use 3.5 years in our model.  If a 
smaller half-life value had been used, the estimates from our CCWD model would 
have decreased more rapidly after exposure stopped, potentially altering the 
composition of the exposure groups.    
Other limitations include the lack of information on smoking status and 
other potential confounders including family history of cancer, access to health 
care services, and other chemical exposures.  
Prostate cancer was inconsistently associated with increasing exposure to 
APFO/PFOA from previous cancer mortality studies with this cohort.  Based on 
past results, prostate cancer was the cause of death of most interest.  In the current 
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 study we evaluated each worker’s individual APFO/PFOA exposure to determine 
the risk outcomes.  We observed a positive dose-response relationship with 
increasing exposure to APFO/PFOA for prostate cancer deaths, but the risk was 
not beyond chance.  It is established that age-related changes in the central region 
and the peripheral zones of the prostate show an increase in size with age (Allen 
et. al., 1989).  Since the prostate takes on physiological changes with age, 
exposures during certain ages may increase sensitivity and susceptibility to 
negative health outcomes.  Our examination of specific windows of exposure did 
not find high exposure during these times to be associated with prostate morality.  
Past studies have alluded to the causes of prostate cancer but have shown mixed 
results, with the exception of a few specific factors.  These factors include age, 
family history, and race, which are all related to prostate cancer (Leitzmann and 
Rohrmann, 2012).  In a recent meta-analysis, prostate cancer mortality was 
positively associated with smoking status.  Smokers had a 14% increase in their 
risk of death compared to non-smokers (Huncharek M. et al., 2010).  Other 
factors, such as prostate cancer screening, have an effect on early diagnosis and 
prognosis.  Potentially, inconsistent findings in prostate mortality studies could be 
related to many uncontrolled variables.  
 Another cancer of concern that has been positively associated with 
APFO/PFOA exposure includes kidney cancer.  Vieira et al. (2013) who studied 
residents living near the DuPont Teflon-manufacturing plant in West Virginia 
(WV) noted evidence of increasing risk for kidney cancer based on high and very 
high exposure categories.  Additionally, an analysis of the DuPont chemical 
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 workers evaluated the SMRs of the employees based on estimated serum-PFOA 
categories from a job-exposure matrix.  Results showed a significant exposure-
response trend for malignant and non-malignant renal disease (Steenland and 
Woskie, 2012).  The findings from the current 3M occupational cohort do not 
support the community or occupational health findings in WV of a positive 
association with exposure to APFO/PFOA and kidney cancer mortality.   
 The primary strengths of this study are the size of the cohort, the almost 
complete case ascertainment and the use of an internal referent-working group, 
which helped reduce potential confounding from the healthy worker effect or 
dissimilar SES.  Additionally, this study was the first to analyze the mortality 
experience of this cohort using time-varying worker exposure profiles from a 
recently created 3M-exposure data matrix.  The validity of future cancer mortality 
and morbidity analyses with this population will be enhanced due to the available 
exposure data. 
  3M completely phased out the production of APFO by the end of 2002.  Exposure in 
this setting is no longer of concern and there is limited evidence that a definitive risk of a 
negative health outcome exists.  The results of the current study show that while a modest 
association is observed for prostate mortality, it is not observed across all analyses.  
There is not a conclusive link between APFO/PFOA and a cancer death due to the 
inconsistent findings depending on the chosen referent group and exposure group 
classifications.  This ongoing work is essential to ensure the safety of workers in other 
locations who may continue to have relatively high occupational exposure to the 
chemical.  
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Table 1.  Characteristics of Cottage Grove and St. Paul 3M Workers 
 St. Paul Cottage Grove Total Population 
No. Workers 4,359 4,668 9,027 
    
No. Male (%), Females (%)  3,833 (88%), 526 (12%)  3716 (79%), 952 (21%)  7,549 (84%), 1478 (16%) 
 (range) 
    
Mean Age at First Employment 29 (16-63) 30 (16-73) 29 (16-73) 
    
Mean Age at Last Employment 49 (19-77) 44 (19-92) 46 (19-92) 
    
Mean Years Worked 20 (1-45) 14 (1-59) 17 (1-59) 
    
Mean Person-Years  39 33 36 
    
Mean Exit Cohort Age 68 62 65 
    
No. of Deaths 1,834 (42%) 1,145 (25%) 2,979 (33%) 
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Table 2.      Characteristics of APFO/PFOA Workers by Exposure Group: All Workers (N=9,027)  
 
Exposure  
Group  
Range 
APFO/PFOA 
mg 
Age at 
First 
Work 
Year* 
Age at 
Exit* 
No. 
Years 
Worked * 
No. 
Males (%) 
No. 
Females (%) 
Person 
Years * 
No. 
Deaths** 
1 0 to 1.0 x 10-3 29 68 19 3,972 (88%) 546 (12%) 39 1,889 (42%) 
         
2 
>1.0 x 10-3 to 
1.0 x 10-2 28 67 3 257 (58%) 184 (42%) 39 118 (27%) 
         
3 
>1.0 x 10-2 to 
1.0 x 10-1 30 61 6 720 (74%) 248 (26%) 30 228 (24%) 
         
4 >0.1 to 1.0 31 63 14 1,372 (80%) 338 (20%) 32 458 (27%) 
         
5 >1.0 to 10 29 61 23 878 (87%) 127 (13%) 32 226 (22%) 
         
6 >10 27 59 24 351 (91%) 35 (9%) 33 61 (16%) 
*Mean, **Row percent 
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Table 3.      Number of Cancer Deaths by APFO/PFOA Exposure Group: All Workers (N=9,027) 
 
Exposure  
Group  
Range  
 APFO/PFOA mg 
No. 
Kidney 
Deaths 
No. 
Bladder 
Deaths 
No. 
Breast 
Deaths 
No. 
Liver 
Deaths  
No. 
Pancreatic 
Deaths 
No. 
Prostate 
Deaths 
Total No. 
Workers 
1 0 to 1.0 x 10-3 18 8 14 7 31 49 4518 
         
2 
>1.0 x 10-3 to 1.0 x 
10-2 0 0 1 0 1 1 467 
         
3 
>1.0 x 10-2 to 1.0 x 
10-1 1 2 4 4 2 3 1010 
         
4 >0.1 to 1.0 4 4 4 3 6 9 1665 
         
5 >1.0 to 10 1 2 2 1 8 7 1031 
         
6 >10 0 0 0 0 0 3 376 
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Table 4. 
 
Standardized Mortality Ratios (SMR): Selected Mortalities for Cottage Grove and St. 
Paul 3M Workers (N=9,027) 
 Cottage Grove    St. Paul  
Cause Observed SMR 95% CI  Observed SMR 95% CI 
        
Cancers        
All Cancers 332 0.87 0.78, 0.97  514 1.04 0.95, 1.13 
Kidney 6 0.53 0.20, 1.16  18 1.23 0.73, 1.95 
Bladder  8 0.89 0.38, 1.75  8 0.62 0.27, 1.22 
Breast 11 0.82 0.41, 1.47  15 1.39 0.78, 2.29 
Liver 8 0.81 0.35, 1.59  7 0.55 0.24, 1.14 
Pancreas 18 0.85 0.50, 1.34  30 1.09 0.74, 1.56 
Prostate 24 0.83 0.53, 1.23  48 1.03 0.76, 1.37 
Other Health        
All Cause 1125 0.85 0.80, 0.90  1828 0.98 0.94, 1.03 
Diabetes 27 0.76 0.50, 1.11  64 1.42 1.09, 1.81 
IHD 248 0.84 0.74, 0.95  443 0.95 0.86, 1.04 
 **Referent rates from MN. Population (1960-2007, IHD=Ischemic Heart Disease 
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Table 5. 
Standardized Mortality Ratios (SMR): Selected Mortalities for Cottage Grove 
3M Workers (N=4,668) 
 Chemical Division-ever   Non-Chemical Division-only  
Cause Observed SMR 95% CI  Observed SMR 95% CI 
        
Cancers        
All Cancers 161 0.94 0.80, 1.10  171 0.81 0.69, 0.94 
Kidney 4 0.75 0.20, 1.92  2 0.34 0.04, 1.21 
Bladder 3 0.73 0.15, 2.13  5 1.02 0.33, 2.40 
Breast 1 0.34 0.01, 1.87  10 0.96 0.46, 1.76 
Liver  4 0.9 0.24, 2.29  4 0.74 0.20, 1.89 
Pancreas 7 0.73 0.29, 1.51  11 0.94 0.47, 1.69 
Prostate 16 1.18 0.67, 1.91  8 0.53 0.23, 1.04 
Other Health        
All Cause 523 0.88 0.81, 0.96  602 0.82 0.75, 0.89 
Diabetes 20 1.27 0.78, 1.96  7 0.36 0.14, 0.74 
IHD 110 0.83 0.68, 1.00  138 0.85 0.72, 1.01 
**Referent rates from MN. Population (1960-2007),  IHD=Ischemic Heart Disease 
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Table 6. 
Hazard Rate Ratios (HR) for Selected Cancer Mortalities 
All 3M Workers: Time-Dependent Estimates from PCD and CCWD Models (N=9,027) 
  
Cause N HR: PCD Model 95% CI  HR: CCWD Model  95% CI 
      
Cancers      
Kidney 24 0.66 0.28, 1.56 0.81 0.44, 1.46 
Bladder 16 0.95 0.71, 1.28 0.96 0.82, 1.14 
Breast  25 0.86 0.54, 1.37 0.99 0.96, 1.02 
Liver 15 0.62 0.18, 2.07 0.89 0.56, 1.44 
Pancreas 48 0.98 0.91, 1.05 0.99 0.99, 1.004 
Prostate 72 1.00 0.99, 1.005 1.00 0.99, 1.002 
*Models adjusted for first work year and gender, PCD=Potential Cumulative Dose and CCWD=Cumulative Clearance Weighted Dose 
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Table 7. 
Hazard Rate Ratios (HR) for Selected Cancer Mortalities 
All 3M Workers: Time-Dependent Exposure Groups from PCD Model (N=9,027) 
 HR: Exposure Groups vs. St. Paul Workers 
Cause N 
Group 1 
(95%CI) N 
Group 2 
(95%CI) 
 
N 
Group 3 
(95%CI) N 
Group 4 
(95%CI) N 
Group 5 
(95%CI) N 
Group 6 
(95%CI) 
             
Cancers             
Kidney 0 - 0 - 1 
0.33 (0.04, 
2.51) 4 
0.75 (0.25, 
2.24) 1 
0.34 (0.05, 
2.56) 0 - 
Bladder 0 - 0 - 2 
1.89 (0.39, 
9.13) 4 
1.73 (0.51, 
5.84) 2 
1.81 (0.38, 
8.69) 0 - 
Breast  0 - 1 
0.22 (0.03, 
1.68) 4 
0.94 (0.30, 
2.94) 4 
0.65 (0.21, 
2.07) 2 
1.12 (0.24, 
5.31) 0 - 
Liver 0 - 0 - 4 
3.62 (1.04, 
12.6) 3 
1.32 (0.34, 
5.19) 1 
0.86 (0.11, 
7.08) 0 - 
Pancreas 1 
1.10 (0.15, 
8.05) 1 
0.37 (0.05, 
2.80) 2 
0.44 (0.11, 
1.85) 6 
0.69 (0.29, 
1.67) 8 
1.80 (0.82, 
3.97) 0 - 
Prostate 1 
0.57 (0.08, 
4.15) 1 
0.38 (0.05, 
2.77) 3 
0.53 (0.17, 
1.72) 9 
0.71 (0.34, 
1.44) 7 
1.22 (0.57, 
2.61) 3 
1.27 (0.30, 
5.28) 
*Models adjusted for first work year and gender,  PCD=Potential Cumulative Dose  
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Table 8. 
Hazard Rate Ratios (HR) for Selected Cancer Mortalities 
All 3M Workers: Time-Dependent Exposure Groups from PCD and CCWD Models (N=9,027) 
 HR: High and Low Exposure Groups in Cottage Grove vs. St. Paul Workers 
Cause N 
Low: PCD 
(95%CI) N 
Low: CCWD 
(95%CI) N 
High: PCD 
(95%CI) N 
High: CCWD 
(95%CI) 
 
(St. 
Paul) 
          
Cancers          
Kidney 1 0.19 (0.03, 1.43) 0 - 5 0.54 (0.19, 1.48) 6 0.54 (0.21, 1.37) 18 
Bladder 2 1.03 (0.21, 4.98) 1 0.82 (0.10, 6.66) 6 1.62 (0.55, 4.79) 7 1.59 (0.56, 4.53) 8 
Breast  5 0.53 (0.19, 1.50) 5 0.88 (0.31, 2.47) 6 0.71 (0.26, 1.79) 6 0.47 (0.17, 1.29) 14 
Liver 4 2.13 (0.69, 7.41) 1 0.89 (0.11, 7.28) 4 1.05 (0.30, 3.67) 7 1.54 (0.53, 4.51) 7 
Pancreas 4 0.50 (0.17, 1.45) 2 0.40 (0.10, 1.69) 14 0.97 (0.51, 1.84) 16 0.91 (0.49, 1.69) 30 
Prostate 5 0.50 (0.19, 1.26) 2 0.30 (0.07, 1.22) 19 0.91 (0.53, 1.56) 22 0.91 (0.97, 1.03) 48 
*Models adjusted for first work year and gender, **Groups 1, 2, and 3 (low) and Groups 4, 5, and 6 (high) 
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Table 9. 
Hazard Rate Ratios (HR) for Selected Cancer Mortalities with a 10-Year Lag Period 
All 3M Workers: Time-Dependent Exposure Groups from PCD and CCWD Models (N=9,027) 
 HR: High and Low Exposure Groups in Cottage Grove vs. St. Paul Workers 
Cause N 
Low: PCD 
(95%CI) N 
Low: CCWD 
(95%CI) N 
High: PCD 
(95%CI) N High: CCWD (95%CI) 
 
(St. 
Paul) 
          
Cancers          
Kidney 1 0.34 (0.08, 1.61) 0 - 5 0.44 (0.15, 1.31) 6 0.45 (0.17, 1.23) 18 
Bladder 2 1.02 (0.21, 4.92) 1 0.80 (0.10, 6.51) 6 1.63 (0.55, 4.81) 7 1.60 (0.57, 4.55) 8 
Breast  5 0.52 (0.19, 1.48) 5 0.85 (0.30, 2.40) 6 0.73 (0.26, 2.01) 6 0.49 (0.18, 1.32) 14 
Liver 4 2.02 (0.58, 7.13) 1 0.79 (0.10, 6.57) 4 1.09 (0.32, 3.78) 7 1.58 (0.54, 4.59) 7 
Pancreas 4 0.73 (0.30, 1.78) 2 0.97 (0.37, 2.52) 14 0.84 (0.42, 1.65) 16 0.75 (0.39, 1.45) 30 
Prostate 5 0.59 (0.25, 1.39) 2 0.44 (0.14, 1.40) 19 0.86 (0.50, 1.49) 22 0.87 (0.52, 1.48) 48 
*Models adjusted for first work year and gender, **Groups 1, 2, and 3 (low) and Groups 4, 5, and 6 (high) 
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Table 10. 
Time-Windows of Exposure: Age 30-39 Hazard Rate Ratios (HR) 
All 3M Workers: Exposure Groups using PCD and CCWD Models (N=9,027) 
 HR: High and Very Low Exposure Groups in Cottage Grove vs. St. Paul Workers 
Cause N 
Very Low: 
PCD (95%CI) N 
Very Low: CCWD 
(95%CI) N 
High: PCD 
(95%CI) N High: CCWD (95%CI) 
 
(St. 
Paul) 
          
Cancers          
Kidney 1 
0.15 (0.02, 
1.11) 0 - 5 0.54 (0.19, 1.47) 6 0.47 (0.19, 1.21) 18 
Bladder 4 
1.50 (0.44, 
5.15) 3 2.17 (0.56, 8.41) 4 1.15 (0.34, 3.86) 5 1.04 (0.34, 3.24) 8 
Breast  6 
0.43 (0.16, 
1.15) 5 0.59 (0.21, 1.65) 5 0.82 (0.28, 2.38) 6 0.51 (0.19, 1.39) 14 
Liver 4 
1.40 (0.38, 
5.12) 2 1.26 (0.23, 6.82) 4 1.06 (0.30, 3.68) 6 1.18 (0.39, 3.57) 7 
Pancreas 9 
0.89 (0.41, 
1.93) 8 1.56 (0.70, 3.50) 9 0.68 (0.32, 1.45) 10 0.55 (0.27, 1.15) 30 
Prostate 10 
0.81 (0.40, 
1.62) 9 1.42 (0.66, 2.91) 14 0.66 (0.36, 1.20) 15 0.55 (0.30, 0.99) 48 
*Models adjusted for first work year and gender, **Groups 1 and 2 (very low) and Groups 3, 4, 5, and 6 (high) 
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Table 11. 
Time-Windows of Exposure: Age 40-49 Hazard Rate Ratios  
All 3M Workers: Exposure Groups using PCD and CCWD Models (N=9,027) 
 HR: High and Very Low Exposure Groups in Cottage Grove vs. St. Paul Workers 
Cause N 
Very Low: PCD 
(95%CI) 
 
Very Low: CCWD 
(95%CI) N High: PCD (95%CI) N 
High: CCWD 
(95%CI) 
 
(St. 
Paul) 
   
 
      
Cancers          
Kidney 2 0.25 (0.06, 1.10) 
 
- 4 0.50 (0.17, 1.49) 6 0.50 (0.20, 1.29) 18 
Bladder 2 0.62 (0.13, 3.00) 
 
1.13 (0.23, 5.52) 6 1.96 (0.67, 5.68) 6 1.36 (0.46, 3.98) 8 
Breast  6 0.43 (0.16, 1.14)  0.39 (0.13, 1.22) 5 0.82 (0.29, 2.34) 7 0.71 (0.27, 1.83) 14 
Liver 3 0.87 (0.22, 3.52)  0.51 (0.06, 4.42) 5 1.51 (0.47, 4.90) 7 1.43 (0.49, 4.22) 7 
Pancreas 6 0.50 (0.20, 1.23)  0.48 (0.14, 1.60) 12 1.04 (0.53, 2.04) 15 0.87 (0.46, 1.64) 30 
Prostate 6 0.39 (0.16, 0.91)  0.63 (0.25, 1.58) 18 0.98 (0.57, 1.69) 19 0.74 (0.43, 1.27) 48 
*Models adjusted for first work year and gender, **Groups 1 and 2 (very low) and Groups 3, 4, 5, and 6 (high) 
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 CHAPTER 6:  DISCUSSION 
  
The relationship between exposure to perfluorooctanoic acid (PFOA) and 
its ammonium salt, ammonium perfluorooctanoate (APFO), and the risk of 
disease in humans has been in question for decades. It is persistent in the 
environment and there are many routes of low-level environmental exposure, with 
98% of the US population having detectable serum-PFOA levels.  Ammonium 
Perfluorooctanoate is a synthetic polyfluorinated chemical and in the presence of 
aqueous media, APFO dissolves to form PFOA [CF3(CF2)6CO2NH4= 
CF3(CF2)6COOH + NH3]  (Griffith and Long, 1980).  It is an eight-chain fully 
fluorinated organic compound that is thermally inert, chemically stable and used 
as a processing aid in the production of fluoropolymers and fluoroelastomers.  
Several animal studies of high level dosing have shown adverse health 
outcomes—including cancer of the liver, testes and pancreas—for cases compared 
to controls (Butenoff et al., 2004, and Biegel at el. 2001).  APFO and PFOA 
produce a range of toxic effects in animals including: cancinogenisis, 
heptotoxicity, immunotoxicity, developmental toxicity and endocrine toxicity; 
and it is possible that exposure may not be innocuous to humans (Biegel et al. 
2001; Butenhoff et al., 2002; Griffith and Long, 1980; Kennedy et al., 2004; and 
Yang et al., 2001).  
At the 3M Cottage Grove plant in Minnesota, APFO was formulated as a 
polymerization aid used in the production of high-performance materials and 
other consumer products from 1947-2002.  In addition to background exposure, 
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 some workers had the opportunity for high-level exposures while producing the 
chemical. Two previously conducted occupational mortality studies with the 
Cottage Grove 3M cohort have shown an association between worker’s exposure 
to APFO and risk of prostate cancer deaths; however, these studies have had 
mixed results depending on the choice of referent group and have imprecise 
estimates due to few cases (Gilliland and Mandel, 1993 and Lundin et al., 2008).  
These occupational studies employed qualitative measures of exposure—
assigning exposure based on the workers’ job title, department or length of 
employment from human resource records.  In the current study we explored the 
relationship between a vast range of more specific quantitative exposure estimates 
and risk of a cancer death.  These APFO/PFOA exposure values were derived 
from air measurements used to calculate daily time-weighted exposure scenarios 
unique for each combination of job title, department and year.  Therefore, the 
current study population of workers was assigned a daily exposure value for each 
day the person was part of the cohort.  From these, we calculated an annual dose 
for each year the person was part of the study.  This occupational study was a 
follow-up study with more than a decade of additional person-time.  There were 
675 new Cottage Gove (to bring the total number of Cottage Grove workers to 
4,668) workers and for the first time the cohort included 4,359 St. Paul workers as 
the referent-working group to bring the total to 9,027 eligible workers.  The 
longer follow-up period and the addition of an internal comparison group of 
workers decreased the potential for systematic and random error.  The aim was to 
reduce the potential effects of confounding with the inclusion of the workers from 
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 St. Paul due to their similar demographic characteristics and socioeconomic 
status.  We used Cox proportional hazard models to evaluate the risk of death.  
We also compared the entire cohort to the state of Minnesota’s population and 
analyzed the two locations separately and two divisions (Chemical and Non-
Chemical) within Cottage Grove using standardized mortality ratios (SMRs).  
Standardized Mortality Ratios 
 Results of this study indicate that when comparing the Cottage Grove 3M 
workers to the Minnesota state population, 3M workers have a lower risk of death 
from all a-priori cancers.  Evaluating the two locations separately, overall we see 
a greater risk of dying from cause-specific cancers including; kidney, breast, 
pancreas, and prostate cancers only in the St. Paul population.  Whereas, there 
was no increase in risk observed in the Cottage Grove group.  The SMRs for the 
workers who were ever employed in the Chemical Division at Cottage Grove 
observed an increase in the risk of a prostate cancer death.  The results were 
imprecise, and based on few cases. 
Hazard Ratios 
 The internal analyses showed that the 3M workers are not at a greater risk 
of death for all a-priori cancers when evaluating the increase in APFO/PFOA 
time-dependent exposure as the predictor variable.  However, there was an 
increase in risk observed with increasing exposure for pancreas and prostate 
cancer deaths compared to the referent group, but these were not beyond chance.  
We observed a greater risk for bladder and liver cancer deaths when evaluating 
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 cumulative exposure groups for exposure only during the 4th and 5th decades of 
life.  However, these results were based on few cases and not significant.   
Limitations 
 We were not able to utilize blood-serum measurements due to the limited 
number of samples and the changes in methodology.  The employee exposure 
profiles were calculated summing the daily mg/m3 of exposure to APFO/PFOA 
from the exposure data matrix.  We used the annual estimates of exposure and the 
breathing rate to calculate milligrams (mg) of inhaled APFO/PFOA—these were a 
proxy for body burden.  The exposure estimates included an exhaustive review of 
historical air measurements in addition to expert knowledge of job locations and 
exposure tasks by job title.  However, these estimates of exposure were not real-
time personal air measurements assigned to individuals in the cohort.  Therefore, 
we have estimates of dose, which are a proxy for body burden.  The relationship 
between serum-PFOA values and inhalation exposure was not evaluated, but 
could prove useful as a verification tool. 
 Other limitations included the inability to explore other types of cancer-
specific deaths (e.g., testicular and thyroid cancers) do to the lack of power from 
the sample size.  The analyses with cancers that have low case-fatality rates, such 
a prostate cancer, would be best evaluated with cancer incidence studies.  
Whereas, pancreatic cancer deaths are a fairly good surrogate for incidence due to 
its high case-fatality rate. 
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 Bias, Study Validity and Sensitivity Analyses 
Confounding can occur when there are unknown or unmeasured variables 
that have not been controlled in the analysis (Greenland et al., 1999; Rothman et 
al., 2008).  Specifically, when a variable that is not controlled for is a cause of the 
disease and also related to the exposure of interest, then the results will not 
represent the true risk.  There may be variables that are causal to the cancers 
evaluated and related to APFO/PFOA exposure in this study but were not 
controlled for due to the lack of information.  However, we created a directed 
acyclic graph (DAG) to aid in the selection of potential confounding covariates in 
this study (Figure 1).  We attempted to control for these with the selection of first 
year of employment as a proxy for wage status, age, number of years worked, and 
other SES and behavioral factors related to both the exposure and outcome.   
Our main cancer of interest was prostate cancer due to findings from the 
previous two occupational studies with this Cottage Grove 3M cohort.  Prostate 
cancer is the sixth leading cause of death from cancer and second most commonly 
diagnosed cancer in men (IARC, 2008).  Several potential factors that influence 
risk of prostate cancer remain and these may have affected the results of the 
current cohort.  Specifically, prostate cancer mortality has been associated with 
smoking status and other factors such as family history and race, which were not 
controlled for in the current study (Huncharek M. et al., 2010, Leitzmann and 
Rohrmann, 2012).  
The other a-priori cancers evaluated have shown various environmental 
and genetic factors associated with increasing risk.  For example, smoking is also 
known to be a major risk factor in the development of bladder, pancreatic, and 
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 breast cancers.  Additionally, certain germ-line mutations and racial status are risk 
factors for both pancreatic and breast cancers (Lowenfels and Maisonneuve, 
2005).  Alcohol consumption has been shown to increase the risk of several 
cancers including pancreatic, breast, liver, and bladder cancers (Grewal P and 
Viswanathen VA, 2012).  As the fifth and seventh most common cause of cancer 
in men and women, respectively—the risk of liver cancer increases with exposure 
to the hepatitis B and C virus, aflatoxins and from some occupational chemical 
exposures, such as vinyl chloride (Cuang Sc, La Vecchia C and Boffetta P, 2009).   
Selection bias can affect the study outcome when the population is not 
representative of the entire cohort.  In epidemiological studies this includes biases 
that come from methods by which participants are chosen from the source 
population and selection or follow-up are not complete (Pearce et al., 2007).  In 
the case of this 3M study, the inclusion criteria were a minimum of one year of 
employment for both locations.  Therefore, the population was similar for all 
exposure groups and the referent population. 
Information bias is the differential classification of the exposure(s) and the 
outcome(s), which may occur from systematic differences in the accuracy of data 
collected (Vandenbroucke et al., 2007).  In this cohort there was potential for 
exposure misclassification; however the probability of exposure misclassification 
would not have been related to disease status and therefore non-differential.  
According to Pearce et al. (2007), non-differential misclassification usually biases 
study results towards to null and can produce false-negative findings.   
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 Sensitivity analyses were conducted to observe the effects from potential 
exposure misclassification and are reported here.  The magnitude and direction of 
the potential impact were examined relative to the defined exposure groups, and 
in particular the middle and highest exposure groupings.  In the most recent 
mortality study of 3M Cottage Grove workers, Lundin et al. (2009) discussed the 
potential for exposure misclassification based on the three designated 
groupings—and in particular the workers who may have had brief but high–level 
exposure episodes (e.g., custodial workers or others assigned to clean-up).  In this 
study an exposure reconstruction with quantitative data were applied, however the 
possibility of misclassification still looms primarily for mid-to high exposure 
groups, where it is possible that some workers had short-term high level 
exposures—such as spills—that were not fully captured.  In an attempt to evaluate 
the significance of potential exposure misclassification and the outcome of a 
cancer death, we have re-parameterized workers who were part of the mid-to 
upper-range exposure groups into one high exposure group.  The hazard ratios 
were re-calculated with group rankings from the cumulative estimates of exposure 
with a time-dependent Cox PH model and the St. Paul group was used as the 
referent population (Table 1).  The results remained unchanged regarding the 
direction of the exposure-response relationship for all cancers evaluated.  There 
was a modest increase in magnitude for kidney, bladder, breast and liver cancer 
deaths when evaluating the workers in the newly formed high group compared to 
the formerly defined high exposure group.  However, only bladder and liver 
cancer deaths were above unity.  Prostate and pancreatic cancer deaths were the 
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 main cancers of interest based on the results from previous studies and the current 
study with this cohort.  The results reported in the current analysis show no 
increase in risk due to APFO/PFOA exposure. 
Another sensitivity analysis for the current paper includes the exploration 
of the intensity of exposure, which was based on how quickly a worker achieved a 
high-level cumulative exposure.  We evaluated three dose-rate groups in order to 
determine if high, yet relatively short-term doses of APFO/PFOA were closely 
associated with the risk of disease compared to low-dose chronic exposure.  This 
could provide insight into effects of workers who may be grouped into a low or 
medium cumulative exposure group, yet may have had higher body burden due to 
one or many short-term intense exposure scenarios.  We divided the total 
cumulative exposure estimates by the number of years worked to get the dose-rate 
groups.  This evaluation was completed with a LOGISTIC procedure in SAS 9.2 
and stratified on groups of “total years worked”.  The three groups included 
workers who had; 1 < 10 years, 10 < 25 years, and => 25 years of work.  We were 
able to compare workers in similar work-length groups to one-another and focus 
on the intensity of exposure per group in an attempt not to introduce confounding.  
Table 2 shows the number of workers per dose-rate group, and table 3 provides 
the number of deaths for each cancer by dose-rate groups.  Table 4 provides the 
Odds Ratios (OR) for each cancer by dose-rate group with group 1 as the referent 
group.  Overall, we observed a non-significant greater risk of bladder cancer death 
for both the middle and high (groups 2 and 3) dose-rate groups compared to the 
referent group.  Both breast and liver cancer deaths show a greater risk of death 
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 only for the middle dose-rate group.  Results are not statistically significant—and 
based on few cases.     
FUTURE RESEARCH 
 
Many new ideas surfaced throughout the development of the research 
hypothesis in this study.  The primary need for future research is a cancer 
incidence study, specifically for prostate cancer.  Although all three studies 
evaluating cancer mortality with this cohort indicate a positive trend for prostate 
mortality with increased exposure to APFO/PFOA, the results are contingent 
upon the referent group and are marked by sparse data.  Prostate cancer has a low 
case-fatality rate (unlike pancreatic and other cancers), and it would be valuable 
to conduct an incidence study using the current exposure data.  Another cancer 
associated with PFOA from toxicological data suggests testicular cancer increases 
with exposure.  Due to small numbers, these analyses were not feasible to conduct 
in the current study and would be of use as well in a future cancer incidence 
evaluation.  Outcomes on cancer incidence related to time-dependent exposure for 
diseases with low case-fatality rates are important in the determination of 
causality.  In addition, a cancer incidence survey would be useful to verify the 
family history of disease, wage status, alcohol consumption, and smoking 
status—unknown variables in the current research and all important contributing 
factors to specific cancers.  
A future analysis may include a different choice of the serum-PFOA half-
life value.  We chose to use the geometric mean of 3.5 years.  This figure was 
taken from a study result based on data from a group of APFO/PFOA chemical 
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 workers at the Cottage Grove location conducted by Olsen et al. (2007).  To 
investigate the potential impact of a shorter half-life (the range was 2.3 to 3.8 
years), it would be of value to re-assess the risk of death in the cohort after re-
calculating annual exposure estimates with an alternative half-life in place of 3.5 
years (e.g., 2.8 years—the lower value within the range).  A shorter half-life 
increases the difference between the primary cumulative model estimates and the 
annual estimate of the elimination model estimates.  Changes in the exposure 
group distribution would be observed and the elimination of APFO at a quicker 
rate would decrease the annual values more rapidly with time. Another 
development is with the use of biological sampling data, specifically serum-
PFOA measurements of the workers.  There were limited data available; however 
this could be used in the future to validate findings with a sub-set of the cohort.  
Finally, the most pressing finding from the mortality analyses in the current study 
is the modest positive dose-response relationship for prostate and pancreatic 
cancer deaths found with increasing exposure to APFO/PFOA by groups.  It 
would be useful to evaluate the significance of high exposure groups relative to 
the lowest exposure group and the impact of a negative health outcome—both 
with a prostate cancer incidence study and a follow-up mortality study. 
CONCLUSION 
 
The long-term goal for this research was to evaluate health outcomes from 
occupational exposure to APFO/PFOA in a group of 3M workers.  Moreover, the 
purpose of this study was to examine the relationship between APFO/PFOA 
exposure and the risk of death from six a priori selected cancers; bladder, breast, 
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 kidney, liver, pancreatic and prostate.  To achieve this goal, we evaluated cancer 
mortality from an occupational cohort with employees who had a broad range of 
APFO/PFOA exposure estimates over the course of more than half a century, and 
compared these workers to other demographically similar workers who never 
directly worked with APFO/PFOA.  The exposure estimates were calculated for 
each worker by using a historical exposure reconstruction matched to the 
workers’ employment history records.  This allowed for a robust, exposure profile 
specific to each worker for the entire length of each individual’s follow-up.  To 
ascertain the risk of cancer mortality we explored the relationship between the 
time-dependent cumulative annual estimates by linking individuals with their 
mortality experience from death records.  The 3M occupational retrospective 
cohort included all workers with a minimum of one year of work beginning in 
1947 and follow-up time ending in 2008.  The findings indicating that an increase 
in occupational exposure to APFO/PFOA increases the risk of cancer mortality 
were not beyond chance.  The overall SMR for the entire cohort was below unity 
and statistically significant 0.93 (95% CI: 0.90, 0.97) demonstrating that the 3M 
workers as a whole have a lower risk of all deaths compared to the Minnesota 
general population.  The two sensitivity analyses showed no change in the 
direction of the outcome, only small changes in magnitude, in particular for 
bladder and liver cancer deaths.  The overall synthesis of analyses and 
conclusions reported herein shows a modest non-significant trend with increasing 
exposure groups and prostate cancer deaths.  This and the SMR of 1.18 (95% CI 
0.7, 1.9) from the sub-group of workers who ever worked in the Chemical 
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 Division compared to the Minnesota state population support the outcome of the 
previous mortality study with this cohort.   
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Table 1. 
Hazard Rate Ratios (HR) for Selected Cancer Mortalities 
All 3M Workers: Time-Dependent Exposure Groups from PCD Model (N=9,027) 
 HR: Med-High and Low Exposure Groups in Cottage Grove vs. St. Paul Workers 
Cause N 
Very Low: 
(95%CI) N Low:  (95%CI) N 
Med-High: 
(95%CI) N High:(95%CI) 
 
(St. Paul) 
          
Cancers          
Kidney 0 - 1 
0.19 (0.03, 
1.43) 6 0.49 (0.19, 1.26) 5 0.54 (0.19, 1.48) 18 
Bladder 0 - 2 
1.03 (0.21, 
4.98) 8 1.69 (0.62, 4.60) 6 1.62 (0.55, 4.79) 8 
Breast  1 0. 20 (0.03, 1.49) 5 
0.53 (0.19, 
1.50) 10 0.81 (0.34, 1.93) 6 0.71 (0.26, 1.79) 14 
Liver 0 - 4 
2.13 (0.69, 
7.41) 8 1.64 (0.58, 4.63) 4 1.05 (0.30, 3.67) 7 
Pancreas 2 0. 56 (0.13, 2.40) 4 
0.50 (0.17, 
1.45) 16 0.84 (0.45, 1.56) 14 0.97 (0.51, 1.84) 30 
Prostate 2 0.45 (0.11, 1.87) 5 
0.50 (0.19, 
1.26) 22 0.83 (0.47, 138) 19 0.91 (0.53, 1.56) 48 
*Models adjusted for first work year and gender,  
**Original Groups 1, 2 and 3 (low) 
Groups 1 and 2 (very low)  
***Original Groups 4, 5, and 6 (high),  
Groups 3, 4, and 5 (med-high) 
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Table 2. 3M Workers: APFO/PFOA Dose-Rate Groups (N=9,027) 
 Number of Workers by Groups 
Work-Year Groups 
Group 1: (< 0.00001) 
mg/year 
Group 2: (=> 0.00001 < 
0.01) mg/year 
Group 3: (=> 0.01) 
mg/year 
    
Group 1:  (1< 10 years) 258 1687 1310 
Group 2: (10< 25 years) 1331 280 1005 
Group 3: (=>25 years) 2016 110 1031 
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Table 3. 
3M Workers: Number of Cancer deaths by Intensity of 
Exposure (N=9,027) 
 Dose-Rate Groups  
Cause Group 1  
 
Group 2 Group 3 
    
Cancers    
Kidney 1 3 4 
Bladder 7 4 5 
Breast  12 8 5 
Liver 6 6 3 
Pancreas 27 9 12 
Prostate 47 11 14 
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Table 4. 
Odds Ratios for Selected Cancer Mortalities 
3M Workers: Dose-Rate Exposure Groups from PCD Model 
 OR: Dose-Rate Groups vs. Lowest Dose-Rate Group 
Cause N Group 2 (95%CI) N Group 3 (95%CI) 
     
Cancers     
Kidney 3 0.19 (0.04, 0.88) 4 0.27 (0.08, 0.88) 
Bladder 4 1.95 (0.42, 9.04) 5 1.58 (0.48, 5.20) 
Breast  8 1.11 (0.33, 3.81) 5 0.65 (0.19, 2.18) 
Liver 6 2.35 (0.56, 9.82) 3 0.81 (0.19, 3.45) 
Pancreas 9 1.0 (0.39, 2.58) 12 1.0 (0.51, 1.98) 
Prostate 11 1.0 (0.41, 2.44) 14 1.0 (0.58, 1.73) 
*Models adjusted for first work year and gender, 
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 Figure 1.  Directed Acyclic Graph: Prostate Cancer 
 
 
 
 
 
 
 
 
 
138 
 
 BIBLIOGRAPHY 
 
 
3M Company (2003a).  Final Report Assessment of lipid, hepatic and thyroid 
function in relation to an occupational biologic limit value for 
perfluorooctanoic acid, 3M Medical Department, June 9, 2003.  US EPA 
Docket No.: AR-226-1351. 
Abdellatif A.G., Preat, V., Taper, H.S. and Roberdfroid, M.  (1991). The 
modulation of rat liver carcinogenesis by perfluorooctanoic acid, a 
peroxisome proliferator. Toxicol. Appl. Pharmacol. (111) 530–537. 
Alexander BH (2001).  Mortality study of workers employed at the 3M Cottage 
Grove Facility, Minneapolis: University of Minnesota. Report No.: U.S. 
EPA Docket AR-226-1030a018. 
Alexander BH, Olsen GW, Burris JM, Mandel JH, Mandel JS. Mortality of 
employees of a perfluorooctanesulphonyl fluoride manufacturing facility. 
Occupational & Environmental Medicine 2003;60(10):722-9. 
 
Allen SK. Kressel HY., Arger PH., and Pollack HM.  Age-related changes of the 
prostate: Evaluation by MR imaging.  AJR 1989. 152: 77-81. 
Andersen, M. E., Clewell, H. J.,3rd, Tan, Y. M., Butenhoff, J. L., & Olsen, G. W. 
(2006). Pharmacokinetic modeling of saturable, renal resorption of 
perfluoroalkylacids in monkeys--probing the determinants of long plasma 
half-lives. Toxicology, 227(1-2), 156-164.  
Andersen, M. E., Butenhoff, J. L., Chang, S. C., Farrar, D. G., Kennedy, G. L.,Jr, 
Lau, C. (2008). Perfluoroalkyl acids and related chemistries--
toxicokinetics and modes of action. Toxicological Sciences, 102(1), 3-14.  
Asakawa, A., Toyoshima, M., Harada, K. H., Fujimiya, M., Inoue, K., & 
Koizumi, A. (2008). The ubiquitous environmental pollutant 
perfluorooctanoicacid inhibits feeding behavior via peroxisome 
proliferator-activated receptor-alpha. International Journal of Molecular 
Medicine, 21(4), 439-445.  
Bartell SM, Calafat AM, Lyu C, Kato K, Ryan PB, Steenland K. 2009. Rate of 
decline in serum PFOA concentrations after granular activated carbon 
filtration at two public water systems in Ohio and West Virginia.  Env. 
Health Perspect 118(2): 222-228. 
139 
 
 Barton, C. A.; Butler, L. E.; Zarzecki, C. J.; Flaherty, J.; Kaiser, M.   
  Characterizing perfluorooctanoate in ambient air near the fence line of a  
  manufacturing facility: comparing modeled and monitored values. J. Air  
  Waste Mange. Assoc. 2006, 56, 48-55. 
 
Begley TH, White K, Honigfort P, Twaroski ML, Neches R, Walker RA. 
Perfluorochemicals: potential sources of and migration from food 
packaging. Food Additives & Contaminants 2005;22(10):1023-31. 
Biegel, L. B., Hurtt, M. E., Frame, S. R., O'Connor, J. C., & Cook, J. C. (2001). 
Mechanisms of extrahepatic tumor induction by peroxisome proliferators in 
male CD rats. Toxicological Sciences, 60(1), 44-55.  
Brede E, Wilhelm M, Göen T, Müller J, Rauchfuss K, Kraft M, et al. 2010. Two-
year follow-up biomonitoring pilot study of residents’ and controls’ PFC 
plasma levels after PFOA reduction in public water system in Arnsberg, 
Germany. Int J Hyg Environ Health 213:217–223. 
 
Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol. 2-The Design 
and Analysis of Cohort Studies. Lyon: International Agency for Research 
on Cancer, 1987. 
 
Bonefeld-Jorgeson EC, Long M, Bossi R, Ayotte P, Asmund G, Kruger T, Ghisari 
A, Mulvad G, Kern P, NZulumiki P, Dewailly E.  2011.  Perfluorinated 
compounds are related to breast cancer risk in Greenlandic Inuit: a case 
control study.  Environ Health 10:88; doi10.1186/1476-069X-10-88 
[Online 6 October 2011]. 
Butenhoff, J., Costa, G., Elcombe, C., Farrar, D., Hansen, K., Iwai, H., et al. 
(2002). Toxicity of ammonium perfluorooctanoate in male cynomolgus 
monkeys after oral dosing for 6 months. Toxicological Sciences, 69(1), 244-
257.  
Butenhoff, J. L., Kennedy, G. L.,Jr, Hinderliter, P. M., Lieder, P. H., Jung, R., 
Hansen, K. J. (2004). Pharmacokinetics of perfluorooctanoate in 
cynomolgus monkeys. Toxicological Sciences, 82(2), 394-406.  
Calafat, A.M., Wong, L.Y., Kuklenyik, Z., Reidy, J.A., & Needham, L.L.  (2007). 
Polyfluoroalkyl chemicals in the U.S. population: Data from the national 
health and nutrition examination survey (NHANES) 2003-2004 and 
comparisons with NHANES 1999-2000. Environmental Health 
Perspectives, 115(11), 1596-1602.  
Checkoway H., Pearce N., Hickey J.S., Dement J.M. 1990  Latency analysis in 
occupational epidemiology.  Archives of Environmental Health, 45(2); 95-
100. 
140 
 
 Chuang SC, La Vecchia C, Boffetta P (2009) Liver cancer: descriptive    
epidemiology and risk factors other than HBV and HCV infection. 286(1): 
9-14. 
Davis M., Hart J., Laden F., Garshick E., Smith T. (2011) A retrospective 
assessment of occupational exposure to elemental carbon in the U.S. 
trucking industry.  Env. Health Per. 119(7), 997-1002. 
Doran E., Fenske R., Kissel J., Curl C., Simcox N. (2003).  Impact of Dermal 
Absorption in Occupational Exposure Assessment:  Comparison of Two 
Models for Agricultural Reentry Workers Exposed to Azinphosmethyl.  
Appl Occu & Env. Hy 18(9), 669-677. 
Dreyer, A.; Weinberg, I.; Temme, C.; Ebinghaus, R. Polyfluorinated Compounds 
in the Atmosphere of the Atlantic and Southern Oceans: Evidence for a 
Global Distribution. Environ.Sci. Technol. 2009, 43, 6507–6514. 
 
Emmett EA, Zhang H, Shofer FS, Freeman D, Rodway NV, Desai C. Community 
exposure to perfluorooctanoate: Relationships between serum levels and 
certain health parameters. J Occup Environ Med 2006, 48:771–779. 
Fairley, K. J., Purdy, R., Kearns, S., Anderson, S. E., & Meade, B. J. (2007). 
Exposure to the immunosuppressant, perfluorooctanoic acid, enhances the 
murine IgE and airway hyper reactivity response to ovalbumin. 
Toxicological Sciences, 97(2), 375-383.  
Fei, C., McLaughlin, J. K., Tarone, R. E., & Olsen, J. (2008). Fetal growth 
indicators and perfluorinated chemicals: A study in the Danish national 
birth cohort. American Journal of Epidemiology, 168(1), 66-72.  
Gallagher L., Vieira V., Ozonoff D., Webster T., Aschengrau A (2011)  Risk of 
breast cancer following exposure to tetrachlroroethylene-contaminated 
drinking water in Cape Cod, Massachusetts: a reanalysis of a case-control 
study using a modified exposure method.  Env. Health 10(1), 47-63. 
Gilliland, F. D., & Mandel, J. S. (1996). Serum perfluorooctanoic acid and hepatic 
enzymes, lipoproteins, and cholesterol: A study of occupationally exposed 
men. American Journal of Industrial Medicine, 29(5), 560-568.  
Gilliland, F. D., and  Mandel, J. S. (1993). Mortality among employees of a 
perfluorooctanoic acid production plant. Journal of Occupational Medicine, 
35(9), 950-954.  
Glaza, S.M. (1995): Acute dermal toxicity study of T-6342 in rabbits. Corning 
Hazelton, Inc., Project ID: HWI50800374, 3M Company, St. Paul, MN. 
141 
 
 Glaza, S.M. (1997): Acute oral toxicity study of T-6669 in rats. Corning Hazalton 
Inc. CHW 61001760. Sponsored by 3M Company, St. Paul, Minnesota.  
Goldenthal, E.I. (1978): Ninety-day subacute rat toxicity study. Final report 
prepared for 3M Company by International Research and Development 
Corporation, St. Paul, MN.  
Gortner, E.G. (1981): Oral teratology study of T-2998 CoC in rats. Safety 
Evaluation Laboratory and Riker Laboratories, Inc., Experiment No. 
0681TB0398, February. 
Grewal P, Viswanathen VA. Liver cancer and alcohol. Clinics in Liver Disease 
  2012; 16(4):839-850. 
Griffith F.D., and Long J.E., (1980) Animal toxicity studies with ammonium 
perfluorooctanoate, American Industrial Hygiene Association Journal (41) 
576–583. 
Guruge, K. S., Yeung, L. W., Yamanaka, N., Miyazaki, S., Lam, P. K., Giesy, J. 
P., et al. (2006). Gene expression profiles in rat liver treated with 
perfluorooctanoic acid (PFOA). Toxicological Sciences, 89(1), 93-107.  
Han, T.A. Snow, R.A. Kemper and G.W. Jepson. (2003) Binding of 
perfluorooctanoic acid to rat and human plasma proteins, Chem Res 
Toxicol (16)775–781. 
Hanhijarvi, H., Ylinen, M., Haaranen, T. and Nevalainen, T. (1988): A proposed 
species difference in the renal excretion of perfluorooctanoic acid in the 
beagle dog and rat. In New development of biosciences: Their 
implications for laboratory animal science (Beynen, A.C. and Solleveld, 
H.A., eds.), pp. 409-412, Martinus Nijhoff Publishers, Dordrecht, 
Netherlands. 
Haughom, B., & Spydevold, O. (1992). The mechanism underlying the 
hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane 
sulphonic acid (PFOSA) and clofibric acid. Biochimica Et Biophysica 
Acta, 1128(1), 65-72.  
Hauptmann, M., Pohlabeln, H., Lubin, J. H., Jöckel, K.-H., Ahrens, W., Brüske-
Hohlfeld, I. and Wichmann, H.-E. (2002), The exposure-time-response 
relationship between occupational asbestos exposure and lung cancer in 
two German case-control studies. American Journal of Industrial 
Medicine, 41: 89–97.  
142 
 
 Houde M, Martin JW, Letcher RJ, Solomon KR, Muir DCG.  Biological 
monitoring of polyfluoroalkyl substances: a review. Environ Sci Technol 
2006, 40:3463–3473. 
 
Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for 
prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J 
Public Health. 2010;100 (4):693–701. 
 
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 
2010; 60 (5):277–300. 
Johnson JD, Gibson SJ, Ober RE (1979) Extent and route of excretion and tissue 
distribution of total carbon-14 in rats after a single i.v. dose of FC-95-14C. 
Project No. 8900310200, Riker Laboratories, Inc., St. Paul, MN [EPA 
Docket No. 8(e)HQ-1180-00374] 
Keller B., Marsman D., Popp J., Thurman R. (1992)  Several nongenotoxic 
carcinogens uncouple mitochondrial phosphorylation.  Biochimica Et 
Biophysica Acta, 1102: 237-244. 
Kennedy, G. L.,Jr, Butenhoff, J. L., Olsen, G. W., O'Connor, J. C., Seacat, A. M., 
Perkins, R. G., et al. (2004). The toxicology of perfluorooctanoate. Critical 
Reviews in Toxicology, 34(4), 351-384.  
Kennedy, G. L.,Jr, Hall, G. T., Brittelli, M. R., Barnes, J. R., & Chen, H. C. 
(1986). Inhalation toxicity of ammonium perfluorooctanoate. Food & 
Chemical Toxicology, 24(12), 1325-1329.  
Kleinbaum DG.  1996.  Survival Analysis: A Self Learning Text  
 
Kreckmann KH, Sakr CJ, Leonard RC, Dawson DJ 2009. Estimation and 
Validation of Biomarker-Based Exposures for Historical Ammonium 
Perfluoroocanoate. J of Occ and Env Hygiene (6),511-516. 
Kuslikis, B. I., Vanden Heuvel, J. P., & Peterson, R. E. (1992). Lack of evidence 
for perfluorodecanoyl- or perfluorooctanoyl-coenzyme A formation in male 
and female rats. Journal of Biochemical Toxicology, 7(1), 25-29.  
Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007. 
Perfluoroalkyl acids: a review of monitoring and toxicological findings. 
Toxicol Sci 99:366–394. 
 
Leitzmann and Rohrmann. 2010. Risk factors for the onset of prostatic cancer:  
 age, location, and behavioral correlates. Clin. Epidemiology. 2012; 4:1-11. 
143 
 
 Lemal D.M. (2004).  Perspective on fluorocarbon chemistry. Journal  Organic 
Chemistry. 69 (1): 1–11. 
Leonard RC, Kreckman KH, Sakr CJ, Symons JM.  2008.  Retrospective cohort 
  mortality study of workers in a polymer production plant including a 
  reference population of regional workers.  Annals of Epi. 18:15-22. 
Loveless S.E., Hoban D., Sykes G., Frame S.R., Everds N.E. (2008) Evaluation of 
the immune system in rats and mice administered linear ammonium 
perfluorooctanoate (APFO).  Toxicological Sciences, 105(1), 86-96. 
Lowenfels AB, MAisonneuve P (2005) Risk factors for pancreatic cancer. J Cell 
 Biochem 95: 649-656. 
 
Lundin J, Alexander B, Olsen G, Church T. 2009. Ammonium perfluorooctanoate 
production and occupational mortality. Epidemiology 20(6):921–928. 
Midasch, O., Drexler, H., Hart, N., Beckmann, M. W., & Angerer, J. (2007). 
Transplacental exposure of neonates to perfluorooctanesulfonate and 
perfluorooctanoate: A pilot study. International Archives of Occupational 
& Environmental Health, 80(7), 643-648.  
Michalik L., Wahli W. (2006) Involvement of PPAR nuclear receptors in tissue 
injury and wound repair. Journal of Clinical Investigation. 116(3):598-
606. 
Miller, J., Flaherty J., Wille R., Buck W., Morandi F., Isemura T. (2007). 
Analysis of Perfluorocarboxylic Acids in Air.  Journal of Occupational 
and Environmental Hygiene, 4(3), 174-183. 
National Cancer Institute.  NCI. SEER data statistic sheets: acceded on February, 
2011 http://seer.cancer.gov/statfacts/html/all.html 
 
National Institute for Occupational Safety and Health (NIOSH).  PC LTAS: Life 
Table Analysis System.  In. Cincinnati: U.S. Department of Health and 
Human Services; 1998. 
Neiuwenhuijsen M, Paustenbach DR and Duarte-Davidson R.2006. New 
developments in exposure assessment: the impact on the practice of health 
risk assessment and epidemiological studies.  Environ Int 32.996-1009. 
Nilsson, R., Beije, B., Preat, V., Erixon, K., & Ramel, C. (1991). On the 
mechanism of the hepatocarcinogenicity of peroxisome proliferators. 
Chemico-Biological Interactions, 78(2), 235-250.  
144 
 
 Olsen GW, Butenhoff JL, Mandel JH. Assessment of lipid, hepatic, and thyroid 
function in relation to an occupational biologic limit value for 
perfluorooctanoate. Saint Paul: 3M Company, 2003. 
Olsen, G. W., Gilliland, F. D., Burlew, M. M., Burris, J. M., Mandel, J. S., & 
Mandel, J. H. (1998). An epidemiologic investigation of reproductive 
hormones in men with occupational exposure to perfluorooctanoic acid. 
Journal of Occupational & Environmental Medicine, 40(7), 614-622.  
Olsen, G.W.,  Zobel, L.R. (2007). Assessment of lipid, hepatic, and thyroid 
parameters with serum perfluorooctanoate (PFOA) concentrations in 
fluorochemical production workers. International Archives of Occupational 
& Environmental Health, 81(2), 231-246.  
Olsen, G. W., Burris, J. M., Ehresman, D. J., Froehlich, J. W., Seacat, A. M., 
Butenhoff, J. L., et al. (2007a). Half-life of serum elimination of 
perfluorooctanesulfonate,perfluorohexanesulfonate,and perfluorooctanoate 
in retired fluorochemical production workers. Environmental Health 
Perspectives, 115(9), 1298-1305.  
Olson C, Andersen M. The acute toxicity of perluorooctanoic and 
 perfluorodecanoic acids in male rats and their effects on fatty tissue. 
 Toxicol Appl Pharmacol. 1983, 70; 362-372. 
Ohmori K, Kudo N, Katayama K, Kawashima Y (2003) Comparison of the 
toxicokinetics between perfluorocarboxylic acids with different carbon 
chain length. Toxicology 184:135–140. 
Palazzolo, M.J. (1993): Thirteen-week dietary toxicity study with T-5180, 
ammonium perfluorooctanoate (CAS No. 3825-26-1) in male rats. Final 
report. Laboratory Project Identification HWI 6329-100, Hazelton, 
Wisconsin Inc. 
Pastoor TP, Lee KP, Perri MA, Gillies PJ (1987) Biochemical and morphological 
studies of ammonium perfluorooctanoate-induced hepatomegaly and 
peroxisome proliferation. Exp Mol Pathol 47:98–109 
Paustenbach, D. J., Panko, J. M., Scott, P. K., & Unice, K. M. (2007). A 
methodology for estimating human exposure to perfluorooctanoic acid 
(PFOA): A retrospective exposure assessment of a community (1951-2003). 
Journal of Toxicology & Environmental Health Part A, 70(1), 28-57.  
Pearce N., Checkoway H., Kriebel D. (2007). Bias in occupational epidemiology 
studies. Occup Eniron Med 64(8): 562-568.   
 
145 
 
 Reddy J., Azarnoff D., Hignite C.  Hypolipidemic hepatic pexoisome proliferators 
from a novel class of chemical carcinogens.  Nature. 1980, 28: 397-398. 
 
SAS Institute Inc. SAS 9.2 for Windows. Cary, NC USA, 2008. 
Sakr, C. J., Leonard, R. C., Kreckmann, K. H., Slade, M. D., & Cullen, M. R. 
(2007). Longitudinal study of serum lipids and liver enzymes in workers 
with occupational exposure to ammonium perfluorooctanoate. Journal of 
Occupational & Environmental Medicine, 49(8), 872-879.  
Simons J, Bryce T. Electrochemical fluorination. In: Simons J, eds.  
Flourine Chemistry.  New York: Academica Press. 1954:340-377. 
 
Skipper PL, Tannenbaum SR, Ross RK, Yu MC. Nonsmoking-related arylamine 
  exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 
  2003;12: 503–7. 
Slavan A, Thomaseth K, Bortot P, and Sartori N 2001 Use of a toxicokinetic 
model in the analysis of cancer mortality in relation to the estimated 
absorbed dose (2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-TCDD).  The 
Science of the Total Env.(274), pp. 21-35. 
Staples R.E., Burgess B.A. and Kerns W (1984). The embryo-fetal toxicity and 
teratogenic potential of ammonium perfluorooctanoate (Apfo) in the rat, 
Fundam. Appl. Toxicol.  (4) 429–440. 
Starkov A.A., Wallace K.B. (2002).  Structural determinants of fluorochemical-
induced mitochondrial dysfunction. Toxicological Sciences, (66) 244-252. 
Steenland K, Fletcher T., Savitz DA. Epidemiological evidence on the health 
effects of perfluorooctanoic acid (PFOA). Environmental Health 
Perspectives, 2010; 118(8):1100-1108. 
 
Steenland K. and Woskie S. Cohort mortality study of workers exposed to 
perfluorooctanoic acid.  Am J of Epidemiol, 2012; 176(10):909-917. 
 
Stock, N. L.; Furdui, V. I.; Muir, D. C. G.; Mabury, S. A. Perfluoroalkyl 
contaminants in the Canadian Arctic: Evidence of atmospheric transport 
and local contamination. Environ. Sci. Technol. 2007, 41, 3529–3536. 
 
Stock L., Ellis D., Martin J., Muir D., Polyfluorinated Telomer Alcohols and 
Sulfonamides in the North America Troposphere.  Environ. Sci. Technol.  
2004, 38, 991-996. 
Tilton S.C., Orner G.A., Benninghoff A.D., Carpenter H., Hendricks J.D., Pereira 
C.B., Williams D.E. (2008). Genomic profiling reveals and alternate 
146 
 
 mechanism for hepatic tumor promotion by perfluorooctanoic acid in 
rainbow trout. Environmental Health Perspectives. 116 (8): 1047-55. 
Telomer Research Program.  Telomer Research Program Update; Presented to 
US EPA-OPPT, November, 25, 2002; US Public Docket AR 226-1141.U.S. 
Environmental Protection Agency (US EPA).  (2005). Draft risk assessment 
of the potential human health effects associated with exposure to 
perfluorooctanoic acid and its salts 
 
US Census Bureau Quick Facts Sheet: accessed on February 7, 2011 
http://quickfacts.census.gov/qfd/states/27/2713456.html 
US EPA (2006). Announcement of Stewardship Program by Administrator 
Stephen L. Johnson.  Available at: 
http://www.epa.gov/oppt/pfoa/pubs/pfoastewardship.htm.Accessed 
September 2008. 
US EPA Exposure Factor Handbook.  August 1997.  Final Report, pg.22. 
 
US EPA SAB Review of EPA’s Draft Risk Assessment of Potential Human 
Health Effects  
 Associated with PFOA and Its Salt.  Report 2006. 
US Department of Health and Human Services; Center for Disease Prevention 
and Control.  Fourth National Report on Human Exposure to 
Environmental Chemicals.  March, 2013. 
Ubel F., Sorenson S., Roach D. (1980). Health status of plant workers exposed to 
fluorochemicals: a preliminary report. American Industrial Hygiene 
Association. (41) 584-589. 
Vanden Heuvel, J. P., Kuslikis, B. I., Van Rafelghem, M. J., & Peterson, R. E. 
(1991). Tissue distribution, metabolism, and elimination of 
perfluorooctanoic acid in male and female rats. Journal of Biochemical 
Toxicology, 6(2), 83-92.  
Vieira VM, Hoffman K, Shin HM, Weinberg JM, Webster TF, Fletcher T. 
Perfluoroooctanoic acid exposure and cancer outcomes in a contaminated 
community:  a geographic analysis.  Environmental Health Perspectives, 
2013; 121(3):318-323. 
Williams PR and Paustenbach DJ. 2003.Reconstruction of benzene exposure for 
the Pilofilm cohort (1936-1976) using Monte Carlo Techniques. Journal 
Toxicol Environ Health 66  677-781. 
 
Yamashita, N.; Kannan, K.; Taniyasu, S.; Horii, Y.; Petrick, G. Gamo, T. A 
 global survey of perfluorinated acids in oceans. Mar. Pollut. Bull. 2005, 
 51, 658-668. 
147 
 
 Yang, Q., Xie, Y., Eriksson, A. M., Nelson, B. D., & DePierre, J. W. (2001). 
Further evidence for the involvement of inhibition of cell proliferation and 
development in thymic and splenic atrophy induced by the peroxisome 
proliferator perfluoroctanoic acid in mice. Biochemical Pharmacology, 62(8), 
1133-1140.  
Yang, Q., Xie, Y., Alexson, S. E., Nelson, B. D., & DePierre, J. W. (2002). 
Involvement of the peroxisome proliferator-activated receptor alpha in the 
immunomodulation caused by peroxisome proliferators in mice. 
Biochemical Pharmacology, 63(10), 1893-1900.  
Yao X. and Zhong L. (2005).  Genotoxi risk and oxidative DNA damage in 
HepG2 cells exposed perfluorooctanoic acid.  Mutat Res. 587 (1-2):38-44. 
Ylinen, M., Hanhijarvi, H., Jaakonaho, J., & Peura, P. (1989). Stimulation by 
oestradiol of the urinary excretion of perfluorooctanoic acid in the male 
rat. Pharmacology & Toxicology, 65(4), 274-277.  
Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the 
 epidemiologic evidence. Cancer Causes Control. 2009;20(10):1799–1810. 
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock 
SJ, Poole C, Schlesselman JJ, Egger M.  Strengthening the reporting of 
observational studies in epidemiology (STROBE); explanation and 
elaboration.  Epidemiology 2007 Nov; 18(6): 805-35. 
 
148 
 
